

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number  
**WO 01/88106 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N 9/00**
- (21) International Application Number: **PCT/DK01/00316**
- (22) International Filing Date: **7 May 2001 (07.05.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**PA 2000 00781** **12 May 2000 (12.05.2000)** **DK**
- (71) Applicants and  
(72) Inventors: **KNECHT, Wolfgang** [DE/DK]; Hamletsgade 8, Lejl. 113, DK-2200 København N (DK). **MUNCH-PE-TERSEN, Birgitte** [DK/DK]; Bavnebjergspark 36, DK-3520 Farum (DK). **PISKUR, Jure** [SI/DK]; Rudolph Berghsgade 22, DK-2100 København Ø (DK).
- (74) Agents: **CRACKNELL, Mark**; c/o NsGene A/S, 93 Ped-erstrupvej, DK-2750 Ballerup\_\_ et al. (DK).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 01/88106 A2**

(54) Title: NOVEL DEOXYNUCLEOSIDE KINASE ENZYME VARIANTS

(57) Abstract: This invention relates to novel multi-substrate deoxyribonucleoside kinase variants. More specifically the invention provides novel deoxyribonucleoside kinase variants derived from insects or lower vertebrates, in particular from *Drosophila melanogaster*, from *Bombyx mori*, or from *Xenopus laevis*, novel polynucleotides encoding multi-substrate nucleoside kinase variants, vector constructs comprising the polynucleotide, host cells carrying the polynucleotide or vector, methods of sensitising cells to prodrugs, method of inhibiting pathogenic agents in warm-blooded animals, and pharmaceutical compositions comprising deoxyribonucleoside kinase variants of the invention.

**BEST AVAILABLE COPY**

## NOVEL DEOXYNUCLEOSIDE KINASE ENZYME VARIANTS

### TECHNICAL FIELD

5 This invention relates to novel multi-substrate deoxyribonucleoside kinase variants. More specifically the invention provides novel deoxyribonucleoside kinase variants derived from insects or lower vertebrates, in particular from *Drosophila melanogaster*, from *Bombyx mori*, or from *Xenopus laevis*, novel polynucleotides encoding multi-substrate nucleoside kinase variants, vector constructs comprising the  
10 polynucleotide, host cells carrying the polynucleotide or vector, methods of sensitising cells to prodrugs, method of inhibiting pathogenic agents in warm-blooded animals, and pharmaceutical compositions comprising deoxyribonucleoside kinase variants of the invention.

15

### BACKGROUND ART

DNA is made of four deoxyribonucleoside triphosphates, provided by the *de novo* and the salvage pathway. The key enzyme of the *de novo* pathway is ribonucleotide reductase, which catalyses the reduction of the 2'-OH group of the  
20 nucleoside diphosphates, and the key salvage enzymes are the deoxyribonucleoside kinases, which phosphorylate deoxyribonucleosides to the corresponding deoxyribonucleoside monophosphates.

Deoxyribonucleoside kinases from various organisms differ in their substrate specificity, regulation of gene expression and cellular localisation. In  
25 mammalian cells there are four enzymes with overlapping specificities, the thymidine kinases 1 (TK1) and 2 (TK2), deoxycytidine kinase (dCK) and deoxyguanosine kinase (dGK) phosphorylate purine and pyrimidine deoxyribonucleosides. TK1 and TK2 are pyrimidine specific and phosphorylate deoxyuridine (dUrd) and thymidine (dThd), and TK2 also phosphorylates deoxycytidine (dCyd). dCK phosphorylates dCyd,  
30 deoxyadenosine (dAdo) and deoxyguanosine (dGuo), but not dThd. dGK phosphorylates dGuo and dAdo. TK1 is cytosolic, and TK2 and dGK are localised in the mitochondria, although recent reports indicate a cytoplasmic localisation of TK2 as well.

In prokaryotic cells, the pattern of deoxyribonucleoside kinases is not very  
35 well clarified. In *E. coli*, there seems to be only one deoxyribonucleoside kinase, which has been characterised as a TK with similarity to the mammalian TK1. The ability to incorporate dCyd, dAdo and dGuo seems to be lacking. In *Lactobacillus acidophilus*, which is deficient in ribonucleotide reductase, the four

deoxyribonucleosides are phosphorylated by three enzymes. In addition to a TK resembling the *E. coli* TK, there are two kinase complexes that phosphorylate dCyd, dAdo and dGuo. Complex I is a dCK/dAK, and complex II is a dGK/dAK.

Several viruses carry a gene for a TK. Herpes viruses have a TK which  
5 also can phosphorylate dCyd as well as TMP and dCMP. The herpetic kinases with the relatively broad substrate specificity have many features in common with the mammalian TK2, dCK and dGK. Poxviruses code for a TK very similar to the mammalian TK1.

So far, however, none of the known viral, bacterial or eukaryotic  
10 deoxyribonucleoside kinases were shown to phosphorylate all four deoxyribonucleosides.

Recently a deoxyribonucleoside kinase from *Drosophila melanogaster* was isolated and named *Drosophila melanogaster* deoxyribonucleoside kinase, *Dm*-dNK [Munch-Petersen B, Piskur J, and Søndergaard L: Four Deoxynucleoside kinase  
15 Activities from *Drosophila melanogaster* Are Contained within a Single Monomeric Enzyme, a New Multifunctional Deoxynucleoside Kinase; J. Biol. Chem. 1998 **273** (7) 3926-3931]. Subsequently the corresponding gene was cloned and over-expressed [Munch-Petersen B, Knecht W, Lenz C, Søndergaard L and Piskur J: Functional expression of a multi-substrate deoxyribonucleoside kinase from *Drosophila*  
20 *melanogaster* and its C-terminal deletion mutants; J. Biol. Chem. 2000 **275** (9) 6673-6679].

The *Drosophila* kinase possessed the ability to phosphorylate all four deoxyribonucleosides. This is in sharp contrast to all known deoxyribonucleoside kinases that have distinct, although partially overlapping substrate specificities.

25 The catalytic rate of deoxyribonucleoside phosphorylation by *Dm*-dNK was, depending on the substrate, 4-20,000-fold higher than reported for any of the mammalian deoxyribonucleoside kinases. The turnover of thymidine was 70-fold higher than catalysed by the thymidine kinase (TK) of Herpes simplex virus 1 (HSV1). Furthermore, *Dm*-dNK was able to phosphorylate a wide range of nucleoside  
30 analogues used in chemotherapy of cancer or to combat viral infections.

The unique kinetic properties of *Dm*-dNK make this enzyme interesting for both biotechnological as well as medical applications.

For example, ddNTPs used for sequencing and dNTPs used for PCR - reactions are produced by chemical synthesis with toxic chemicals leading to a  
35 number of by-products. Efficient enzymatic synthesis of monophosphates from (di-)deoxyribonucleosides would be one of the key steps in enzymatic production of nucleotides, and *Dm*-dNK with its broad substrate acceptance and high catalytic rates would be an obvious candidate for this task.

An additional example is the use of deoxyribonucleoside kinases as suicide genes in gene therapy of cancer or in genetic pharmaco-modulation therapy of viral infections. The basic concept here is to transduce cancer or viral infected cells with the gene encoding HSV1-TK and subsequently expose them to a nucleoside analogue. The activation of the nucleoside analogue to a cytotoxic or antiviral compound will be potentiated by the transduced kinase. This concept has demonstrated to increase the effects of cytotoxic or antiviral nucleoside analogues in combination with HSV1-TK, human deoxycytidine kinase (dCK) and human deoxyguanosine kinase (dGK). The key step in activation of the majority of the nucleoside analogues is the conversion to the monophosphate.

Therefore the kinetic properties of the enzymes catalysing this step are important both for the efficacy and selectivity of these drugs and there is a need to identify better enzymes for further development of this therapeutic concept. *Dm*-dNK with its unique kinetic properties has been proposed as a candidate for this purpose [Johansson M, Van Rompay A R, Degreves B, Balzarini J and Karlsson A: Cloning and characterization of the multisubstrate deoxynucleoside kinase of *Drosophila melanogaster*; J. Biol. Chem. 1999 **274** (34) 23814-23819; and Munch-Petersen et al.; J. Biol. Chem. 2000 **275** (9) 6673-6679].

Recently, in an effort to find better suicide gene-prodrug combinations for gene therapy, mutants of HSV1-TK with improved specificity for the nucleoside analogues 3'-azido-2',3'-dideoxythymidine (Zidovudine, Retrovir<sup>®</sup>, AZT), ganciclovir (Cytovene<sup>®</sup>, GCV) and aciclovir (Zovirax<sup>®</sup>, ACV) have been genetically engineered by primer mediated random mutagenesis or DNA family shuffling [Black M E, Newcomb T G, Wilson H M P and Loeb L A: Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy; Proc. Natl. Acad. Sci. USA 1996 **93** 3523529; Christians F C, Scapozza L, Crameri A, Folkers G and Stemmer W P C: Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling; Nat. Biotechnol. 1999 **17** 259-264; and Kokoris M S, Sabo P, Adman E T and Black M E: Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant; Gene Therapy 1999 **6** 1415-1426].

Nucleoside analogues with changes in the 2'-deoxyribose moiety are important drugs in medicine and precursors for nucleotides frequently used in biotechnology.

## SUMMARY OF THE INVENTION

It is an object of the present invention to provide novel deoxyribonucleoside kinase variants with increased relative catalytic efficiencies towards different

substrates. This object is met by the provision of novel multi-substrate deoxyribonucleoside kinase variants.

Accordingly, in its first aspect, the invention provides isolated, mutated polynucleotides encoding multi-substrate deoxyribonucleoside kinase enzymes, which  
5 mutated polynucleotide, when compared to the non-mutated polynucleotide, and upon transformation into a bacterial or eukaryotic cell, decreases at least 4 fold the lethal dose (LD<sub>100</sub>) of at least one nucleoside analogue.

In another aspect the invention provides isolated deoxyribonucleoside kinase variants encoded by the polynucleotide of the invention.

10 In a third aspect the invention provides vector constructs comprising the polynucleotide of the invention.

In a fourth aspect the invention provides packaging cell lines capable of producing an infective virion comprising comprising a viral vector of the invention.

In a fifth aspect the invention provides host cells carrying the mutated  
15 polynucleotide of the invention, or the vector of the invention.

In a sixth aspect the invention provides methods of sensitising cells to prodrugs, which methods comprises the steps of transfecting said cell with a polynucleotide sequence of the invention encoding an enzyme that promotes the conversion of said prodrug into a (cytotoxic) drug; and delivering said prodrug to said  
20 cell; wherein said cell is more sensitive to said (cytotoxic) drug than to said prodrug.

In a seventh aspect the invention provides methods of inhibiting pathogenic agents in warm-blooded animals, which methods comprises administering to said animals a mutated polynucleotide of the invention, or a vector of the invention.

In an eight aspect the invention provides pharmaceutical compositions  
25 comprising a mutated polynucleotide of the invention, or a vector of the invention.

In a ninth aspect the invention provides pharmaceutical compositions comprising the enzyme variant of the invention, and a pharmaceutically acceptable carrier or diluent.

Other objects of the invention will be apparent to the person skilled in the art  
30 from the following detailed description and examples.

## DETAILED DISCLOSURE OF THE INVENTION

### Mutant Polynucleotides

35 In its first aspect the invention provides isolated, mutated polynucleotides encoding insect or lower vertebrate deoxyribonucleoside kinase enzymes.

The mutant polynucleotides of the invention include DNA, cDNA and RNA sequences, as well as anti-sense sequences, and include naturally occurring, synthetic,

and intentionally manipulated polynucleotides. The mutant polynucleotides of the invention also include sequences that are degenerate as a result of the genetic code.

As defined herein, the term "polynucleotide" refers to a polymeric form of nucleotides of at least 10 bases in length, preferably at least 15 bases in length. By 5 "isolated polynucleotide" is meant a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes recombinant DNA which is incorporated into an expression vector, into an autonomously replicating plasmid or virus, or into the genomic 10 DNA of a prokaryote or eukaryote, or which exists as a separate molecule, e.g. a cDNA, independent from other sequences.

As defined herein a mutant polynucleotide is a nucleotide sequence that differs at one or more nucleotide positions when compared to the non-mutated (native, wild-type or parent) nucleotide sequence. The mutated polynucleotide of the invention 15 may in particular hold a nucleotide sequence encoding a nucleoside kinase variant having an amino acid sequence that has been changed at one or more positions when compared to the native, wild-type or parent kinase enzyme.

In a preferred embodiment the mutated polynucleotide holds a nucleotide sequence encoding a nucleoside kinase variant having an amino acid sequence that 20 has been changed at one or more positions located in the non-motif regions, and/or at only one motif region, as defined by Table 1, below.

In another preferred embodiment the mutated polynucleotide of the invention, upon transformation into a bacterial or eukaryotic cell, is capable of decreasing at least 4 fold, more preferred at least 8 fold, most preferred at least 10 25 fold the lethal dose (LD<sub>100</sub>) of at least one nucleoside analogue, as compared to the non-mutated (wild-type) polynucleotide. In a more preferred embodiment the nucleoside analogue is aciclovir (9-[2-hydroxy-ethoxy]-methyl-guanosine), bucciclovir, famciclovir, ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]-guanosine), penciclovir, valciclovir, trifluorothymidine, AZT (3'-azido-3'-deoxythymidine), AIU (5'- 30 iodo-5'-amino-2',5'-dideoxyuridine), ara-A (adenosine-arabinoside; Vivarabine), ara-C (cytidine-arabinoside), ara-G (9-beta-D-arabinofuranosylguanine), ara-T, 1-beta-D-arabinofuranosyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2',5'-dideoxyuridine, 1-[2-deoxy-2-fluoro-beta-D-arabino furanosyl]-5-iodouracil, idoxuridine (5-iodo-2'-deoxyuridine), fludarabine (2-Fluoroadenine 9-beta-D-Arabinofuranoside), 35 gencitabine, 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), 2',3'-dideoxythymidine (ddT), 2',3'-dideoxyadenosine (ddA), 2',3'-dideoxyguanosine (ddG), 2-chloro-2'-deoxyadenosine (2CdA), 5-fluorodeoxyuridine, BVaraU ((E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil), BVDU (5-bromovinyl-deoxyuridine),

FIAU (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil), 3TC (2'-deoxy-3'-thiacytidine), dFdC gemcitabine (2',2'-difluorodeoxycytidine), dFdG (2',2'-difluorodeoxyguanosine), or d4T (2',3'-didehydro-3'-deoxythymidine).

In yet another preferred embodiment the mutated polynucleotide of the invention, upon transformation into a bacterial or eukaryotic cell, is capable of decreasing at least 4 fold, preferably at least 8 fold, most preferred at least 10 fold, the lethal dose (LD<sub>100</sub>) of at least two different nucleoside analogues, which analogues are based on two different sugar moieties and two different base moieties.

In a preferred embodiment, the mutated polynucleotide of the invention has the DNA sequence presented as SEQ ID NOS: 9 or 11.

### Enzyme Variants

In another aspect the invention provides substantially pure deoxyribonucleoside kinase variants.

In the context of this invention, the term "enzyme variant" covers a polypeptide (or a protein) having an amino acid sequence that differs from that of the native, parent or wild-type enzyme at one or more amino acid positions, i.e. its primary amino acid sequence has been modified. Such enzyme variants include the variants described in more detail below, as well as conservative substitutions, splice variants, isoforms, homologues from other species, and polymorphisms.

The novel enzyme variants of the invention may in particular be obtained from a mutated polynucleotide of the invention using standard recombinant DNA technology.

In a preferred embodiment enzyme variants of the invention are derived from a multi-substrate kinase. As defined herein, the term "multi-substrate" refers to a deoxyribonucleoside kinase enzyme capable of having the ability to phosphorylate all four native nucleosides, dC, dA, dG and dT (Thd). The ability to phosphorylate all four native nucleosides may be determined by the ratio of maximal specific enzyme activity (enzyme activity/amount of enzyme) for dT, and for any of these nucleosides (maximal specific enzyme activity for dT / maximal specific enzyme activity for dC, dG or dA). This ratio preferably is in the range of from 0.01 to 100.

In a preferred embodiment the enzyme variant of the invention, in comparison to the wild-type enzyme, has been altered with respect to

(i) the ratio " $k_{cat}/K_m(\text{substrate}) / k_{cat}/K_m(\text{nucleoside analogue})$ " (i.e. the ratio between on the one side " $k_{cat}/K_m$ " for at least one native substrate, and on the other side " $k_{cat}/K_m$ " for at least one nucleoside analogue) is decreased by at least at least 5 fold, more preferred at least 10 fold, most preferred at least 20 fold; and/or

(ii) the feedback inhibition by deoxyribonucleoside triphosphate (dNTP), and in particular thymidine triphosphate (TTP), is decreased by at least 1.5 fold, more preferred at least 2 fold, as determined by its IC<sub>50</sub> value using 2 or 10 µM thymidine (dThd) as a substrate.

5 In a preferred embodiment the enzyme variant of the invention, in comparison to the wild-type enzyme, decreases at least 4 fold, preferably at least 8 fold, most preferred at least 10 fold, the lethal dose (LD<sub>100</sub>) of at least two different nucleoside analogues, which analogues are based on two different sugar moieties and two different base moieties.

10

#### dNK Numbering System

In the context of this invention, amino acid residues (as well as nucleic acid bases) are specified using the established one-letter symbol.

By aligning the amino acid sequences of the known deoxyribonucleoside kinase enzymes, a specific amino acid numbering system may be employed, by which  
15 system it is possible to unambiguously allot an amino acid position number to any amino acid residue in any nucleoside kinase enzyme, which amino acid sequence is known.

Such an alignment is presented in Table 1, below. In this table, the first N-terminal amino acid residue (i.e. methionine; M) of *Dm*-dNK carries number 51, and the  
20 last C-terminal amino acid residue (i.e. arginine; R) of *Dm*-dNK carries number 358.

In the context of this invention this numbering system is designated the dNK Numbering System.

In describing the various enzyme variants produced or contemplated according to the invention, the following nomenclatures have been adapted for ease of  
25 reference:

#### *Original amino acid / Position / Substituted amino acid*

According to this nomenclature the substitution of alanine for valine at position 167 is designated as "V167A".

A deletion of methionine at position 51 is designated "M51\*".

30 An insertion of an additional amino acid residue, in this example arginine, e.g. adjacent to position 62, may be designated "T62TR" or "\*63R" (assumed that no position exists for this position in the amino acid sequence used for establishing the numbering system).

An insertion of an amino acid residue, in this example glutamine, at a position  
35 which exists in the established numbering system, but where no amino acid residue is actually present, may be designated "-116Q".

In this way "*Dm*-dNK/I199M/N216S/M217V/D316N" specifies the particular variant that may be derived from the *Drosophila melanogaster* deoxyribonucleoside



kinase by substitution of methionine for isoleucine at position 199, and substitution of serine for asparagine at position 216, and substitution of valine for methionine at position 217, and substitution of asparagine for aspartic acid at position 316, the positions being determined in accordance with Table 1 below.

- 5 Other enzyme variants, derived from the same or from different sources, are identified in the same manner.

Table 1

10 Multiple Sequence Alignment  
dNK Numbering

	Dm-dNK	-----	-----	-----	-----	-----	MAEAASCARK	060
15	BmK	-----	-----	-----	-----	-----	-----	
	XenK	MSVLLAARTC	IRLCCTEHKT	GALARFNLGA	NTALTVRRIA	SALCG-RCNI	MRRGILPSGS	
	hu-TK2	-----	-----	-----	-----	-----	--MGAFQCRP	
	hu-dGK	-----	-----	-----	--MAAGRLFL	SRLRA-PFSS	MAKSPLEGVS	
	hu-dCK	-----	-----	-----	-----	-----	MATPPKRSCP	
20	HSV1-TK	-----	-----	----MASYPG	HQHASAFDQA	ARSRGHSNRR	TALRPRRQQE	
	Dm-dNK	GT-KYAEQTQ	P--FTVLIEG	<u>NIGSGK</u> TTYL	NHFEKY--KN	DICLLTEPVE	KWRNV-----	120
25	BmK	---MSANNVK	P--FTVFVEG	<u>NIGSGK</u> TTFL	EHFRQF--E	DITLLTEPVE	MWRDL-----	
	XenK	TGNGLKSREK	S--TVICVEG	<u>NIASGK</u> TSCL	DYFSNT--P	DLEVFK <u>EPVA</u>	KWRNV-----	
	hu-TK2	SSDKEQEKEK	K--SVICVEG	<u>NIAGGK</u> TTCL	EFFSNA--T	DVEVLTEPVS	KWRNV-----	
	hu-dGK	SSRGLHAGRG	P--RRLSIEG	<u>NIAVGK</u> STFV	KLLTKT--YP	EWHVATEPVA	TWQNIQAAGN	
	hu-dCK	SFSASSEGTR	I--KKISIEG	<u>NIAAGK</u> STFV	NILKQL--CE	DWEVVPEPVA	RWCNVQSTQD	
30	HSV1-TK	ATEVRPEQKM	PTLLRVYIDG	<u>PHGMGK</u> TTTT	QLLVALGSRD	DIVYVPEPMT	YWRVLGAS--	
			. . . *	***		. . . **	*	
			Motif 1			Motif 2		
	Dm-dNK	-----	NGVNLEELMY	K-DP-----	-----KKWA	MPFQSYVTLT	M--LQSHTAP	180
35	Bm-dNK	-----	KGCNLEELMY	K-DP-----	-----EKWA	MTFQSYVSLT	M--LDMHRRP	
	Xen-dNK	-----	CGHNPLGLMY	Q-DP-----	-----NKWG	LTLQTYVQLT	M--LDIHTKP	
	hu-TK2	-----	RGHNPLGLMY	H-DA-----	-----SRWG	LTLQTYVQLT	M--LDRHTRP	
	hu-dGK	---QKACTAQ	SLGNLLDMMY	R-EP-----	-----ARWS	YTFQTFVSFLS	R--LKVQLEP	
	hu-dCK	EFEELTMSQK	NGGNVLQMMY	E-KP-----	-----ERWS	FTFQTYACLS	R--IRAQLAS	
40	HSV1-TK	-----	---ETIANIY	TTQHRLDQGE	ISAGDAAVVM	TSAQITMGMP	YAVTDAVLAP	
			. . . *			*		
	Dm-dNK	TNKKLK----	-----IM	<u>ERSIFSAR</u> --	<u>YCFVENMRRN</u>	GSLEQGMINT	LEEWYKFIEE	240
45	Bm-dNK	APTPVK----	-----LM	<u>ERSLFSAR</u> --	<u>YCFVEHIMRN</u>	NTLHPAQFAV	LDEWFRFIQH	
	Xen-dNK	SISPVK----	-----MM	<u>ERSIYSAR</u> --	<u>YIFVENLYQS</u>	GKMPAVDYAI	LTEWFKWIVK	
	hu-TK2	QVSSVR----	-----LM	<u>ERSIHSAR</u> --	<u>YIFVENLYRS</u>	GKMPEVDYV	LSEWFDWILR	
	hu-dGK	FPEKLLQ---	ARKPVQ--IF	<u>ERSVYSAR</u> --	<u>YIFAKNLFEN</u>	GSLSDIEWHI	YQDWHSFLLW	
	hu-dCK	LNGKLLD---	AEKPV--FF	<u>ERSVYSAR</u> --	<u>YIFASNLYES</u>	ECMNETEWI	YQDWHWMMN	
50	HSV1-TK	HIGGEAGSSH	APPPALTLIF	<u>DRHPAALLC</u>	<u>YPAARYLMGS</u>	MTPQAVLAFV	ALIPPTLPGT	
			. . . *	*				
			Motif 3		Motif 4			

30	<i>Dm</i> -dNK	<i>Drosophila melanogaster</i> deoxyribonucleoside kinase [Munch-Petersen B, Knecht W, Lenz C, Søndergaard L and Piskur J; <u>J. Biol. Chem.</u> 2000 <b>275</b> (9) 6673-6679; GenBank ACCN AF226281; Presented as SEQ ID NO: 1]
	<i>Bm</i> -dNK	<i>Bombyx mori</i> deoxyribonucleoside kinase [GenBank ACCN AF226281; Presented as SEQ ID NO: 3, obtained as described in Example 3]
35	<i>Xen</i> -dNK	<i>Xenopus laevis</i> deoxyribonucleoside kinase [GenBank ACCN AF250861; Presented as SEQ ID NO: 5, obtained as described in Example 3]
	hu-TK2	Human thymidine kinase 2 [GenBank ACCN O00142; Johansson M & Karlsson A; <u>J. Biol. Chem.</u> 1997 <b>272</b> (13) 8454-8458]
	hu-dGK	Human deoxyguanosine kinase [GenBank ACCN Q16854; Johansson M & Karlsson A; <u>Proc. Natl. Acad. Sci. U.S.A.</u> 1996 <b>93</b> (14) 7258-7262]
40	hu-dCK	Human deoxycytidine kinase [GenBank ACCN P27707; Chottiner, E.G., et al.; <u>Proc. Natl. Acad. Sci. U.S.A.</u> 1991 <b>88</b> (4) 1531-1535]
	HSV1-TK	Herpes simplex virus thymidine kinase [GenBank ACCN CAA23742; McKnight SL; <u>Nucleic Acids Res.</u> 1980 <b>8</b> (24) 5949-5964]
	<b>"Motif"</b>	designates a preserved motif of amino acids
45	-	indicates absent (no) amino acid at this position.
	*	indicates positions which have a single, fully conserved residue.
	.	indicates that one of the following "conservative" groups is fully conserved: -STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY or FYW.

In another preferred embodiment, the enzyme variant of the invention, when compared to the wild-type enzyme, has been mutated

- (i) in a non-motif and/or a non-conserved region; and/or
- 5 (ii) in only one motif and/or conserved region; and/or
- (iii) in any conserved position.

In a yet more preferred embodiment, the enzyme variant of the invention, when compared to the wild-type enzyme, has been mutated

- (i) in a non-motif; and/or
- 10 (ii) in only one motif region; and/or
- (iii) in any conserved position.

As defined herein a motif region designates any of the positions located within the any of the five motif regions identified in Table 1 above. A non-motif region is any region containing amino acid residues not belonging to a motif region as  
15 defined above.

As defined herein conserved positions are those positions and regions containing the amino acid residues marked with an asterisk (\*) or with a period (.) in Table 1. In a preferred embodiment the conserved region is selected from those regions containing amino acid residues marked with an asterisk (\*) only, i.e. those  
20 holding a single fully conserved residue. A non-conserved region is any region containing amino acid residues not belonging to the conserved positions as defined above.

In another preferred embodiment, the enzyme variant of the invention, when compared to the wild-type enzyme, holds a mutation (incl. substitutions,  
25 additions and deletions) at one or more of the following positions 51, 62, 82, 91, 100, 102, 107, 112, 114, 134, 138, 139, 140, 164, 167, 168, 171, 199, 202, 207, 211, 213, 214, 216, 217, 220, 222, 228, 229, 274, 277, 281, 283, 284, 307, 309, 316, 318, 321, 334, 347, and 352 (dNK numbering).

In a more preferred embodiment the enzyme variant of the invention, when  
30 compared to the wild-type enzyme, comprises a substitution conservative to those of G80, N81, I82, G83, S84, G85, K86, T87, T88, E107, P108, V109, E110, K111, W112, Y140, Q164, E201, R202, S203, C210, Y211, C212, P258, R265, I266, R267, Q268, R269, A270, R271, E274, L279, L282, or L293 (dNK numbering).

As defined herein, the term "conservative substitutions" denotes the  
35 replacement of an amino acid residue by another, biologically similar residue. Examples of conservative substitutions include

- (i) the substitution of one non-polar or hydrophobic residue such as alanine, leucine, isoleucine, valine, proline, methionine, phenylalanine or

tryptophan for each other, in particular the substitution of alanine, leucine, isoleucine, valine or proline for each other; or

(ii) the substitution of one neutral (uncharged) polar residue such as serine, threonine, tyrosine, asparagine, glutamine, or cysteine for another, in particular the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine; or

(iii) the substitution of a positively charged residue such as lysine, arginine or histidine for another; or

(iv) the substitution of a negatively charged residue such as aspartic acid or glutamic acid for another.

The term conservative substitution also includes the use of a substituted amino acid residue in place of a parent amino acid residue, provided that antibodies raised to the substituted polypeptide also immuno-react with the un-substituted polypeptide.

In a yet more preferred embodiment the enzyme variant of the invention, when compared to the wild-type enzyme, comprises one or more of the following variations M51T; T62A; N91D; N100D; I102T; N114D; N134D; N134S; L138S; M139L; M139V; V167A; V167S; V167M; T168A; M171R; I199M A207D; V214A; N216S; M217V; N220S; S222W; Y228C; N229S; V277A; Y281H; S307P; K309R; D316N; N318D; N321S; F334L; L347P; and K352N (dNK numbering).

In an even more preferred embodiment the enzyme variant of the invention, when compared to the wild-type enzyme, comprises the following variations

M51T/T168A/N220S;

T62A/V167A/N321S;

N91D/N134D;

N100D/N134D;

N100D/N134D/N318D/L347P;

N100D/N134D/I199M/N216S/M217V/D316N;

I102T/N318D;

N114D/M217V/Y281H;

N134S/L138S/M139L/K352N;

M139V/N318D/L347P;

V167A/M171R/A207D;

V167S/M171R/A207D;

V167A/I199M/N216S/M217V/D316N;

V167A/N318D/L347P;

T168A/N318D/L347P;

T168A/I199M/N216S/M217V/D316N;

M171R/A207D;  
 I199M/V214A/N216S/M217V/D316N;  
 I199M/N216S/M217V/N229S/S307P/D316N;  
 I199M/N216S/M217V/D316N;  
 5 S222W/F334L;  
 Y228C/V277A/K309R; or  
 N318D/L347P (dNK numbering).

In a preferred embodiment the enzyme variant of the invention is derived from a human thymidine kinase 2 (hu-TK2); or a human deoxyguanosine kinase  
 10 (hu-dGK); or a human deoxycytidine kinase (hu-dCK); or a Herpes simplex virus thymidine kinase (HSV1-TK).

In another preferred embodiment the enzyme variant of the invention is derived from an insect or a lower vertebrate, in particular from a *Drosophila melanogaster* deoxyribonucleoside kinase (*Dm*-dNK), or a *Bombyx mori*  
 15 deoxyribonucleoside kinase (*Bm*-dNK), or a *Xenopus laevis* deoxyribonucleoside kinase (*Xen*-dNK), or an *Anopheles gambia* deoxyribonucleoside kinase.

In a more preferred embodiment the enzyme variant of the invention is *Dm*-dNK/M51T; *Dm*-dNK/M51T/T168A/N220S; *Dm*-dNK/T62A; *Dm*-dNK/T62A/V167A/N321S; *Dm*-dNK/N91D; *Dm*-dNK/N91D/N134D; *Dm*-dNK/N100D;  
 20 *Dm*-dNK/N100D/N134D; *Dm*-dNK/N100D/N134D/N318D/L347P; *Dm*-dNK/N100D/N134D/I199M/N216S/M217V/D316N; *Dm*-dNK/I102T; *Dm*-dNK/I102T/N318D; *Dm*-dNK/N114D; *Dm*-dNK/N114D/M217V/Y281H; *Dm*-dNK/N134D; *Dm*-dNK/N134S; *Dm*-dNK/N134S/L138S/M139L/K352N; *Dm*-dNK/L138S; *Dm*-dNK/M139L; *Dm*-dNK/M139V; *Dm*-dNK/M139V/N318D/L347P; *Dm*-  
 25 dNK/V167A; *Dm*-dNK/V167A/I199M/N216S/M217V/D316N; *Dm*-dNK/V167A/N318D/L347P; *Dm*-dNK/T168A; *Dm*-dNK/V167A/M171R/A207D, *Dm*-dNK/V167S/M171R/A207D, *Dm*-dNK/T168A/N318D/L347P; *Dm*-dNK/T168A/I199M/N216S/M217V/D316N; *Dm*-dNK/M171R/A207D *Dm*-dNK/I199M; *Dm*-dNK/I199M/V214A/N216S/M217V/D316N; *Dm*-  
 30 dNK/I199M/N216S/M217V/N229S/S307P/D316N; *Dm*-dNK/I199M/N216S/M217V/D316N; *Dm*-dNK/V214A; *Dm*-dNK/N216S; *Dm*-dNK/M217V; *Dm*-dNK/N220S; *Dm*-dNK/S222W; *Dm*-dNK/S222W/F334L; *Dm*-dNK/Y228C; *Dm*-dNK/Y228C/V277A/K309R; *Dm*-dNK/N229S; *Dm*-dNK/V277A; *Dm*-dNK/Y281H; *Dm*-dNK/S307P; *Dm*-dNK/K309R; *Dm*-dNK/D316N; *Dm*-dNK/N318D;  
 35 *Dm*-dNK/N318D/L347P; *Dm*-dNK/N321S; *Dm*-dNK/F334L; *Dm*-dNK/L347P; or *Dm*-dNK/K352N (dNK numbering).

In another preferred embodiment the enzyme variant of the invention is; *Bm*-dNK/E91D; *Bm*-dNK/E91D/N134D; *Bm*-dNK/-100D; *Bm*-dNK/-100D/N134D; *Bm*-

dNK/-100D/N134D/K347P; *Bm*-dNK/-100D/N134D/L199M/H216S/I217V/D316N; *Bm*-dNK/I102T; *Bm*-dNK/N114D; *Bm*-dNK/N114D/I217V/Y281H; *Bm*-dNK/N134D; *Bm*-dNK/N134S; *Bm*-dNK/N134S/L138S/M139L/K352N; *Bm*-dNK/L138S; *Bm*-dNK/M139L; *Bm*-dNK/M139V; *Bm*-dNK/M139V/K347P; *Bm*-dNK/V167A; *Bm*-  
 5 dNK/V167A/L199M/H216S/I217V/D316N; *Bm*-dNK/V167A/Q321S; *Bm*-dNK/V167A/K347P; *Bm*-dNK/V167A/M171R/A207D, *Bm*-dNK/V167S/M171R/A207D, *Bm*-dNK/S168A; *Bm*-dNK/S168A/L199M/H216S/I217V/D316N; *Bm*-dNK/S168A/N220S; *Bm*-dNK/S168A/K347P; *Bm*-dNK/M171R/A207D; *Bm*-dNK/L199M; *Bm*-  
 10 dNK/L199M/H216S/I217V/D316N; *Bm*-dNK/L199M/V214A/H216S/I217V/D316N; *Bm*-dNK/I199M/H216S/I217V/A229S/D316N; *Bm*-dNK/V214A; *Bm*-dNK/H216S; *Bm*-dNK/I217V; *Bm*-dNK/N220S; *Bm*-dNK/T222W; *Bm*-dNK/F228C; *Bm*-dNK/F228C/V277A/P309R; *Bm*-dNK/V277A; *Bm*-dNK/A229S; *Bm*-dNK/Y281H; *Bm*-dNK/P309R; *Bm*-dNK/D316N; *Bm*-dNK/Q321S; *Bm*-dNK/L334L; *Bm*-dNK/K347P; or  
 15 *Bm*-dNK/K352N (dNK numbering).

In a third preferred embodiment the enzyme variant of the invention is *Xen*-dNK/M51T; *Xen*-dNK/M51T/Q168A; *Xen*-dNK/G62A; *Xen*-dNK/G62A/V167A/E321S; *Xen*-dNK/-100D; *Xen*-dNK/-100D/N134D; *Xen*-dNK/-100D/N134D/E318D; *Xen*-dNK/-100D/N134D/N216S/L217V; *Xen*-dNK/L102T; *Xen*-dNK/L102T/E318D; *Xen*-  
 20 dNK/N114D; *Xen*-dNK/N114D/L217V/Y281H; *Xen*-dNK/N134D; *Xen*-dNK/N134S; *Xen*-dNK/N134S/L138S/M139L; *Xen*-dNK/L138S; *Xen*-dNK/M139L; *Xen*-dNK/M139V; *Xen*-dNK/M139V/E318D; *Xen*-dNK/V167A; *Xen*-dNK/V167A/N216S/L217V; *Xen*-dNK/V167A/E318D; *Xen*-dNK/V167A/M171R/A207D, *Xen*-dNK/V167S/M171R/A207D, *Xen*-dNK/Q168A; *Xen*-dNK/Q168A/N216S/L217V; *Xen*-  
 25 dNK/Q168A/E318D; *Xen*-dNK/M171R/A207D; *Xen*-dNK/V214A; *Xen*-dNK/V214A/N216S/L217V; *Xen*-dNK/N216S; *Xen*-dNK/N216S/L217V; *Xen*-dNK/N216S/L217V/A229S; *Xen*-dNK/L217V; *Xen*-dNK/K222W; *Xen*-dNK/Y228C; *Xen*-dNK/Y228C/I277A/P309R; *Xen*-dNK/A229S; *Xen*-dNK/I277A; *Xen*-dNK/Y281H; *Xen*-dNK/P309R; *Xen*-dNK/E318D; or *Xen*-dNK/E321S (dNK numbering).

30

### Hybrid Enzymes

In a particularly preferred embodiment, the deoxyribonucleoside kinase variant of the invention may be a hybrid deoxyribonucleoside kinase derived from two or more insect multi-substrate deoxyribonucleoside kinases.

35 The hybrid deoxyribonucleoside kinase of the invention should contain at least 5, preferably at least 10, more preferred at least 15, even more preferred at least 20, most preferred at least 25 consecutive amino acids derived from each insect multi-substrate deoxyribonucleoside kinases.

In a preferred embodiment the hybrid kinase enzyme is derived from a *Drosophila melanogaster* deoxyribonucleoside kinase, and/or a *Bombyx mori* deoxyribonucleoside kinase, and/or a *Xenopus laevis* deoxyribonucleoside kinase, and/or an *Anopheles gambia* deoxyribonucleoside kinase.

- 5 In a more preferred embodiment, the hybrid kinase enzyme of the invention is derived from a *Drosophila melanogaster* deoxyribonucleoside kinase and a *Bombyx mori* deoxyribonucleoside kinase, and comprises the amino acid sequence presented as SEQ ID NO: 10, or the amino acid sequence presented as SEQ ID NO: 12.

## 10 Recombinant Vectors

Within another aspect the invention provides a recombinant vector comprising the mutant polynucleotide of the invention.

- As defined herein, a recombinant vector is an expression vehicle or recombinant expression construct used for introducing polynucleotides into a desired  
15 cell. The expression vector may be a virus vector or a plasmid vector, in which the polynucleotide of the invention may be inserted in a forward or reverse orientation. The vector may also be a synthetic gene.

- Suitable expression vehicles include, but are not limited to eukaryotic vectors, prokaryotic vectors, e.g. bacterial linear or circular plasmids, viral vectors,  
20 DNA-protein complexes, e.g. DNA-monoclonal antibody complexes, and receptor-mediated vectors. The vector may in particular be contained within a liposome.

- Preferred bacterial vectors include pQE30, pQE70, pQE60, pQE-9 (available from Quigen); pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (available from Stratagene); pGEX-2T, PKK223-  
25 3, pKK233-3, pDR540 and pRIT5 (available from Pharmacia); and pASK75 (available from Biometra).

- Preferred eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1, pSG (available from Stratagene); pSVK3, pBPV, pMSG, pSVL (available from Pharmacia); and pTEJ-8 [FEBS Lett. 1990 267 289-294] and pcDNA-3 (available from  
30 Invitrogen). Preferred yeast vectors include pYES2 (available from Invitrogen).

Preferred viral vectors include herpes simplex viral vectors, adenoviral vectors, adenovirus-associated viral vectors, pox vectors, parvoviral vectors, baculovirus vectors and retroviral vectors.

- However, any other plasmid or vector may be used as long as they are  
35 replicable and viable in the production host.

The expression vector may further comprise regulatory sequences in operable combination with the polynucleotide sequence of the invention. As defined herein, the term "in operable combination" means that the operable elements, i.e.

gene(s) and the regulatory sequences, are operably linked so as to effect the desired expression. Promoters are examples of such regulatory sequences.

In a preferred embodiment the vector of the invention comprises a promoter operably linked to the polynucleotide.

5 The regulatory elements may be selected from any desired source and the vector produced using standard techniques known in the art, e.g. those described by *Sambrook et al.* [*Sambrook et al.: Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Lab., Cold Spring Harbor, NY 1989].

In a preferred embodiment, the vector is a viral vector, in particular a  
10 herpes simplex viral vector, an adenoviral vector, an adenovirus-associated viral vector, or a retroviral vector. The choice of vector and its regulatory elements of course depends on the purpose of the expression, and is within the discretion of the person skilled in the art.

In yet another aspect the invention provides packaging cell lines capable of  
15 producing an infective virion comprising the virus vector of the invention.

#### Host/Production Cells

In a yet further aspect the invention provides a production cell genetically manipulated to comprise the polynucleotide sequence of the invention, and/or or a  
20 recombinant expression vector of the invention. The cell of the invention may in particular be genetically manipulated to transiently or stably express, over-express or co-express polypeptide of the invention. Methods for generating transient and stable expression are known in the art.

The polynucleotide of the invention may be inserted into an expression  
25 vector, e.g. a plasmid, virus or other expression vehicle, and operatively linked to expression control sequences by ligation in a way that expression of the coding sequence is achieved under conditions compatible with the expression control sequences. Suitable expression control sequences include promoters, enhancers, transcription terminators, start codons, splicing signals for introns, and stop codons,  
30 all maintained in the correct reading frame of the polynucleotide of the invention so as to permit proper translation of mRNA. Expression control sequences may also include additional components such as leader sequences and fusion partner sequences.

The promoter may in particular be a constitutive or an inducible promoter. When cloning in bacterial systems, inducible promoters such as pL of bacteriophage  
35  $\lambda$ , plac, ptrp, ptac (ptrp-lac hybrid promoter), may be used. When cloning in mammalian systems, promoters derived from the genome of mammalian cells, e.g. the ubiquitin promoter, the TK promoter, or the metallothionein promoter, or from mammalian viruses, e.g. the retrovirus long terminal repeat, the adenovirus late



promoter or the vaccinia virus 7.5K promoter, may be used. Promoters obtained by recombinant DNA or synthetic techniques may also be used to provide for transcription of the polynucleotide of the invention.

Suitable expression vectors typically comprise an origin of expression, a  
5 promoter as well as specific genes which allow for phenotypic selection of the transformed cells, and include vectors like the T7-based expression vector for expression in bacteria [*Rosenberg et al*; Gene 1987 **56** 125], the pTEJ-8, pUbi1Z, pcDNA-3 and pMSXND expression vectors for expression in mammalian cells [*Lee and Nathans*, J. Biol. Chem. 1988 **263** 3521], baculovirus derived vectors for  
10 expression in insect cells, and the oocyte expression vector PTLN [*Lorenz C, Pusch M & Jentsch T J*: Heteromultimeric CLC chloride channels with novel properties; Proc. Natl. Acad. Sci. USA 1996 **93** 13362-13366].

In a preferred embodiment, the cell of the invention is an eukaryotic cell, e.g., a mammalian cell, e.g., a human cell, a dog cell, a monkey cell, a rat cell or a  
15 mouse cell, an oocyte, or a yeast cell. The cell of the invention may be without limitation a human embryonic kidney (HEK) cell, e.g., a HEK 293 cell, a BHK21 cell, a Chinese hamster ovary (CHO) cell, a *Xenopus laevis* oocyte (XLO) cell. In another embodiment, the cell of the invention is a fungal cell, e.g., a filamentous fungal cell. In another preferred embodiment, the cell is an insect cell, most preferably the Sf9 cell.  
20 Additional preferred mammalian cells of the invention are PC12, HiB5, RN33b cell lines and human neural progenitor cells. Most preferred are human cells.

When the cell of the invention is an eukaryotic cell, incorporation of the heterologous polynucleotide of the invention may in particular be carried out by infection (employing a virus vector), by transfection (employing a plasmid vector),  
25 using calcium phosphate precipitation, microinjection, electroporation, lipofection, or other physical-chemical methods known in the art.

In a more preferred embodiment the isolated polynucleotide sequence of the invention, and/or or a recombinant expression vector of the invention are transfected in a mammalian host cell, a neural progenitor cell, an astrocyte cell, a T-cell, a  
30 hematopoietic stem cell, a non-dividing cell, or a cerebral endothelial cell, comprising at least one DNA molecule capable of mediating cellular immortalization and/or transformation.

Activation of an endogenous gene in a host cell may be accomplished by introducing regulatory elements, in particular by the introducing a promoter capable of  
35 effecting transcription of an endogenous gene encoding the enzyme variant of the invention.

### Method of Producing the Polypeptides

In another aspect the present invention provides a method of producing an isolated enzyme variant of the invention. In the method of the invention, a suitable production cell is genetically engineered by the introduction of exogenous polynucleotides to allow for expression of the enzyme variant, and the cell is cultured under conditions permitting the production of the polypeptide, followed by recovery of the desired polypeptide.

The polynucleotide of the invention may be incorporated into a desired production or host cell by methods known in the art, e.g. those described by 10 *Sambrook et al.* [*Sambrook et al.: Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Lab., Cold Spring Harbor, NY 1989]. Any technique that facilitates the introduction of exogenous polynucleotides into the desired cell may be employed, including methods like transduction, transfection, transformation, infection, etc.

The polynucleotide of the invention may in particular be obtained by site 15 directed mutagenesis, or even by random mutagenesis.

The polynucleotide of the invention may be derived from any suitable source. The polynucleotide of the invention preferably is derived from an insect or a lower vertebrate. In a more preferred embodiment, which the polynucleotide of the invention is derived from, or produced on the basis of on the basis of any publically 20 available cDNA library.

In a preferred embodiment the polynucleotide of the invention may be obtained using the PCR primers described in the working examples and presented as SEQ ID NOS: 7-8 and 13-20.

The isolated polynucleotide of the invention may be obtained by methods 25 known in the art, e.g. those described in the working examples below.

### Biological Activity

In contrast to most known deoxyribonucleoside kinases that have distinct, although partially overlapping substrate specificities and efficiencies, the 30 deoxyribonucleoside kinase variants of the invention show increased relative efficiencies towards different substrates when compared to the wild-type enzyme.

In a preferred embodiment the ratio " $k_{cat}/K_m(\text{substrate}) / k_{cat}/K_m(\text{nucleoside analogue})$ " (i.e. the ratio between on the one side " $k_{cat}/K_m$ " for at least one native substrate, and on the other side " $k_{cat}/K_m$ " for at least one nucleoside analogue) is 35 decreased by at least at least 5 fold, more preferred at least 10 fold, most preferred at least 20 fold.

As defined herein a kinase enzyme variant is considered to have increased sensitivity if its phosphorylating activity increases more than one fold over the wild-type (parent) enzyme in respect of one or more of its substrates.

In a preferred embodiment the different substrate is a nucleoside analogue.

5 Preferred nucleoside analogues include aciclovir (9-[2-hydroxy-ethoxy]-methyl-guanosine), bucciclovir, famciclovir, ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]-guanosine), penciclovir, valciclovir, trifluorothymidine, AZT (3'-azido-3'-thymidine), AIU (5'-iodo-5'-amino-2',5'-dideoxyuridine), ara-A (adenosine-arabinoside; Vivarabine), ara-C (cytidine-arabinoside), ara-G (9-beta-D-  
10 arabinofuranosylguanine), ara-T, 1-beta-D-arabinofuranosyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2',5'-dideoxyuridine, 1-[2-deoxy-2-fluoro-beta-D-arabino-  
furanosyl]-5-iodouracil, idoxuridine (5-iodo-2'-deoxyuridine), fludarabine (2-  
Fluoroadenine 9-beta-D-Arabinofuranoside), gencitabine, 2',3'-dideoxyinosine (ddI),  
2',3'-dideoxycytidine (ddC), 2',3'-dideoxythymidine (ddT), 2',3'-dideoxyadenosine  
15 (ddA), 2',3'-dideoxyguanosine (ddG), 2-chloro-2'-deoxyadenosine (2CdA), 5-  
fluorodeoxyuridine, BVaraU ((E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil),  
BVDU (5-bromovinyl-deoxyuridine), FIAU (1-(2-deoxy-2-fluoro-beta-D-  
arabinofuranosyl)-5-iodouracil), 3TC (2'-deoxy-3'-thiacytidine), dFdC gemcitabine  
(2',2'-difluorodeoxycytidine), dFdG gemcitabine (2',2'-difluorodeoxyguanosine), or  
20 d4T (2',3'-didehydro-3'-deoxythymidine).

Gene therapy has recently emerged as a new method of therapeutic intervention to treat various cancers. In addition this approach can be used to combat viral infections and has applications in transplantation technology. The basis of this therapy is that a kinase gene is introduced into target cells where the gene will be  
25 expressed. The introduced kinase can then specifically activate otherwise harmless pro-drugs, which in the activated form are toxic and either will lead to cell death or inhibition of virus replication.

Deoxynucleoside analogues like AZT (Zidovudine, Retrovir®), ddC (Zalcitabine, Hivid®) or AraC (Cytarabine) are widely used to treat cancer and virus  
30 infected patients. In target cells these pro-drugs must be anabolised to their triphosphate form to become toxic and lead to cell death or to inhibit virus replication. The rate-limiting step in this activation process is the phosphorylation to the nucleoside monophosphate. However, phosphorylation of many nucleoside analogues is often inefficient in the target cells, or it occurs also un-specifically in non-target  
35 cells.

The efficacy and selectivity of these drugs can be greatly improved using the pro-drug-activating genes coding for the deoxynucleoside kinase variants of the present invention.

So, viewed from one aspect the invention provides methods of sensitising cells to prodrugs, which method comprises the steps of

- (i) transfecting said cell with a polynucleotide sequence of the invention encoding an enzyme that promotes the conversion of said prodrug into a (cytotoxic) drug; and
  - (ii) delivering said prodrug to said cell;
- wherein said cell is more sensitive to said (cytotoxic) drug than to said prodrug.

In a preferred embodiment of this aspect the prodrug is a nucleoside analogue. In a more preferred embodiment, the nucleoside analogue is aciclovir (9-[2-hydroxy-ethoxy]-methyl-guanosine), buciclovir, famciclovir, ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]-guanosine), penciclovir, valciclovir, trifluorothymidine, AZT (3'-azido-3'-thymidine), AIU (5'-iodo-5'-amino-2',5'-dideoxyuridine), ara-A (adenosine-arabinoside; Vivarabine), ara-C (cytidine-arabinoside), ara-G (9-beta-D-arabinofuranosylguanine), ara-T, 1-beta-D-arabinofuranosyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2',5'-dideoxyuridine, 1-[2-deoxy-2-fluoro-beta-D-arabino furanosyl]-5-iodouracil, idoxuridine (5-iodo-2'-deoxyuridine), fludarabine (2-Fluoroadenine 9-beta-D-Arabinofuranoside), gencitabine, 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), 2',3'-dideoxythymidine (ddT), 2',3'-dideoxyadenosine (ddA), 2',3'-dideoxyguanosine (ddG), 2-chloro-2'-deoxyadenosine (2CdA), 5-fluorodeoxyuridine, BVaraU ((E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil), BVDU (5-bromovinyl-deoxyuridine), FIAU (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil), 3TC (2'-deoxy-3'-thiacytidine), dFdC gemcitabine (2',2'-difluorodeoxycytidine), dFdG (2',2'-difluorodeoxyguanosine), or d4T (2',3'-didehydro-3'-deoxythymidine).

Viewed from another aspect the invention provides means and methods for combating pathogenic agents in a subject, which subject may in particular be a warm-blooded animal including a human.

In a preferred embodiment the invention provides a method of inhibiting a pathogenic agent in a warm-blooded animal, which method comprises administering to said animal a polynucleotide sequence of the invention, or a vector of the invention.

In a more preferred embodiment, the polynucleotide sequence or said vector is administered *in vivo*.

In another preferred embodiment, the pathogenic agent is a virus, a bacteria or a parasite.

In yet another preferred embodiment, the pathogenic agent is a tumour cell, or an autoreactive immune cell.

The method of the invention for inhibiting a pathogenic agent in a warm-blooded animal further comprising the step of administering a nucleoside analogue to said warm-blooded animal.

In a preferred embodiment the nucleoside analogue is aciclovir (9-[2-hydroxy-ethoxy]-methyl-guanosine), bucciclovir, famciclovir, ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]-guanosine), penciclovir, valciclovir, trifluorothymidine, AZT (3'-azido-3'-thymidine), AIU (5'-iodo-5'-amino-2',5'-dideoxyuridine), ara-A (adenosine-arabinoside; Vivarabine), ara-C (cytidine-arabinoside), ara-G (9-beta-D-arabinofuranosylguanine), ara-T, 1-beta-D-arabinofuranosyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2',5'-dideoxyuridine, 1-[2-deoxy-2-fluoro-beta-D-arabino furanosyl]-5-iodouracil, idoxuridine (5-iodo-2'-deoxyuridine), fludarabine (2-Fluoroadenine 9-beta-D-Arabinofuranoside), gencitabine, 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), 2',3'-dideoxythymidine (ddT), 2',3'-dideoxyadenosine (ddA), 2',3'-dideoxyguanosine (ddG), 2-chloro-2'-deoxyadenosine (2CdA), 5-fluorodeoxyuridine, BVaraU ((E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil), BVDU (5-bromovinyl-deoxyuridine), FIAU (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil), 3TC (2'-deoxy-3'-thiacytidine), dFdC gemcitabine (2',2'-difluorodeoxycytidine), dFdG (2',2'-difluorodeoxyguanosine), or d4T (2',3'-didehydro-3'-deoxythymidine).

20

### Pharmaceutical Compositions

In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the enzyme variant of the invention.

For use in therapy the enzyme variant of the invention may be administered in any convenient form. In a preferred embodiment, the enzyme variant of the invention is incorporated into a pharmaceutical composition together with one or more adjuvants, excipients, carriers and/or diluents, and the pharmaceutical composition prepared by the skilled person using conventional methods known in the art.

30 art.

Such pharmaceutical compositions may comprise the enzyme variant of the invention, or antibodies hereof. The composition may be administered alone or in combination with one or more other agents, drugs or hormones.

The pharmaceutical composition of this invention may be administered by any suitable route, including, but not limited to oral, intravenous, intramuscular, inter-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, anteral, topical, sublingual or rectal application, buccal,

35

vaginal, intraorbital, intracerebral, intracranial, intraspinal, intraventricular, intracisternal, intracapsular, intrapulmonary, transmucosal, or via inhalation.

Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack  
5 Publishing Co., Easton, PA).

The active ingredient may be administered in one or several doses per day. Currently contemplated appropriate dosages are between 0.5 ng enzyme variant/kg body weight to about 50 µg/kg per administration, and from about 1.0 ng/kg to about 100 µg/kg daily.

10 The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.

In further embodiments, the enzyme variant of the invention may be  
15 administered by genetic delivery, using cell lines and vectors as described below under methods of treatment. To generate such therapeutic cell lines, the polynucleotide of the invention may be inserted into an expression vector, e.g. a plasmid, virus or other expression vehicle, and operatively linked to expression control sequences by ligation in a way that expression of the coding sequence is achieved  
20 under conditions compatible with the expression control sequences. Suitable expression control sequences include promoters, enhancers, transcription terminators, start codons, splicing signals for introns, and stop codons, all maintained in the correct reading frame of the polynucleotide of the invention so as to permit proper translation of mRNA. Expression control sequences may also include  
25 additional components such as leader sequences and fusion partner sequences.

### Methods of Treatment

The present invention, which relates to polynucleotides and proteins, polypeptides, peptide fragments or derivatives produced therefrom, as well as to  
30 antibodies directed against such proteins, peptides or derivatives, may be used for treating or alleviating a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the activity of a cytotoxic agent.

The disorder, disease or condition may in particular be a cancer or a viral infection.

35 The enzyme variants of the present invention may be used directly via, e.g., injected, implanted or ingested pharmaceutical compositions to treat a pathological process responsive to the enzyme variant.

The polynucleotide of the invention, including the complementary sequences thereof, may be used for the expression of the enzyme variant of the invention. This may be achieved by cell lines expressing such proteins, peptides or derivatives of the invention, or by virus vectors encoding such proteins, peptides or derivatives of the invention, or by host cells expressing such proteins, peptides or derivatives. These cells, vectors and compositions may be administered to treatment target areas to affect a disease process responsive to cytotoxic agents.

Suitable expression vectors may be derived from lentiviruses, retroviruses, adenoviruses, herpes or vaccinia viruses, or from various bacterially produced plasmids, and may be used for *in vivo* delivery of nucleotide sequences to a whole organism or a target organ, tissue or cell population. Other methods include, but are not limited to, liposome transfection, electroporation, transfection with carrier peptides containing nuclear or other localising signals, and gene delivery via slow-release systems. In still another aspect of the invention, "antisense" nucleotide sequences complementary to the nucleotide of the invention or portions thereof, may be used to inhibit or enhance enzyme variant expression.

In yet another aspect the invention relates to a method of treating or alleviating a disorder, disease or condition of a living animal body, including a human, which disorder or disease is responsive to the activity of cytotoxic agents.

## BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is further illustrated by reference to the accompanying drawing, in which:

Fig. 1 shows the influence of the nucleotide analogue concentrations [PTP or 8-oxo-dGTP; 2.5, 5.0, 10.0, 20.0, 50.0, 100.0 and 200.0  $\mu\text{M}$ , respectively] in the mutagenic PCR on TK activity [relative number of colonies on TK selection plates (0-60%)];

Figs. 2A-D show the kinetic patterns for the inhibition of thymidine phosphorylation by TTP. Initial velocities of *rDm*-dNK (Fig. 2A) and *rMuD* (Fig. 2B) are showed as a function of varied dThd at fixed TTP concentrations. Double-reciprocal plots of the same data (Fig. 2C for *rDm*-dNK; and Fig. 2D for *rMuD*) demonstrate the type of inhibition. [Figs. 2A and 2C:  $\bullet$  0  $\mu\text{M}$  TTP,  $\blacksquare$  9.8  $\mu\text{M}$  TTP,  $\blacktriangle$  29.3  $\mu\text{M}$  TTP,  $\blacktriangledown$  48.9  $\mu\text{M}$  TTP; Figs. 2B and 2D:  $\bullet$  0  $\mu\text{M}$  TTP,  $\blacksquare$  500  $\mu\text{M}$  TTP,  $\blacktriangle$  1000  $\mu\text{M}$  TTP,  $\blacktriangledown$  2000  $\mu\text{M}$  TTP]. The solid lines represents the best fits of the equations calculated as described in Example 2 (Analysis of Kinetic Data).

## EXAMPLES

The invention is further illustrated with reference to the following examples which are not intended to be in any way limiting to the scope of the invention as claimed.

5

### Example 1

#### PCR Induced *Dm*-dNK Variants

A directed evolution approach, based on mutagenic PCR, was employed to generate mutant kinase forms. The open reading frame (ORF) for *Dm*-dNK was  
10 mutagenized using different nucleotide analogue concentrations and the influence of the different nucleotide analogue concentrations was investigated. The mutagenized PCR fragments were ligated into an expression plasmid and subsequently transformed into the TK deficient *E. coli* strain KY895.

#### 15 Random mutagenesis and mutant library construction

The expression-vector pGEX-2T-r*Dm*-dNK [*Munch-Petersen et al., J. Biol. Chem.* 2000 **275** (9) 6673-6679] was used as template for PCR mutagenesis.

The open reading frame (ORF) for *Dm*-dNK was amplified using the following primers:

20 Dm-TK3: 5'-CGCGGATCCATGGCGGAGGCAGCATCCT-3' (SEQ ID NO: 7); and

Dm-TK4: 5'-CGGAATTCTTATCTGGCGACCCTCTGGCGT-3' (SEQ ID NO: 8).

PCR was done in 2 steps. The first PCR was done in 20 µl reactions with  
25 0.15 units Taq Polymerase from Amersham Corp. in the supplied buffer. Template DNA 10 fmol, primers with 20 pmol each, dNTPs at 0.2 mM each were used. The nucleotide analogues 6-(2-deoxy-β-D-erythropentofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5C][1,2]oxazine-7-one-5'-triphosphate (dPTP) and 2'-Deoxy-8-hydroxyguanosine-5'-triphosphate (8-oxo-dGTP), both available from Amersham Corp., were present at  
30 concentrations as shown in Fig. 1.

PCR conditions were: Denaturation at 94°C for 5 minutes, 25 cycles with 94°C for 45 seconds, 50°C for 45 seconds, 72°C for 2 minutes and finally prolongation at 72°C for 10 minutes.

The PCR products were purified with the PCR purification kit from  
35 Boehringer Mannheim and eluted in 80 µl of 5 mM Tris/HCl pH 7.5. 40 µl of this eluate was used in the second PCR without nucleotide analogues, which was done in a volume of 65 µl with 0.5 units Taq Polymerase, 65 pmol of each primer, 0.2 mM of



each dNTP. PCR conditions were the same as in the first PCR, but cycling was done for 15 cycles only.

The mutagenized PCR fragments were purified by the PCR Kit from Boehringer Mannheim, cut with *Bam*HI and *Eco*RI and sub-cloned into the multiple cloning site of the pGEX-2T plasmid vector. The TK deficient *E. coli* strain KY895 [F *tdk-1 ilv*] [Igarashi K, Hiraga S & Yura T: A deoxythymidine kinase deficient mutant of Escherichia coli. II. Mapping and transduction studies with phage  $\Phi$ 80; Genetics 1967 57 643-654], was electro-transformed with the ligation mix, using standard techniques, and plated on LB-ampicillin (100  $\mu$ g/ml) plates.

10 The relative number of colonies carrying re-circularised vector was determined by colony PCR of randomly picked clones.

#### Degree of mutagenicity

The influence of different nucleotide analogue concentrations in the mutagenic PCR was investigated. The degree of mutagenicity was evaluated as the loss of TK activity. This was done by replica plating of at least 500 colonies from LB-ampicillin plates to TK selection plates [Black M E, Newcomb T G, Wilson H M P & Loeb L A: Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy; Proc. Natl. Acad. Sci. USA 1996 93 3525-3529] and counting the number of colonies surviving on the TK selection plates. Results were corrected for the re-circularisation of the vector.

#### Selection of mutants

First, colonies were selected for restored TK activity by replica plating them on TK selection plates [Black M E, Newcomb T G, Wilson H M P & Loeb L A: Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy; Proc. Natl. Acad. Sci. USA 1996 93 3525-3529]. Only mutants complementing the TK negative *E. coli* strain KY895 give rise to colonies on this selection medium.

30 Overnight cultures of these colonies were diluted 200-fold in 10% glycerol and 2  $\mu$ l drops of the dilution were spotted on M9 minimal medium plates [Ausubel F, Brent R, Kingston R E, Moore D D, Seidman J G, Smith J A & Struhl K (Eds.): Short protocols in molecular biology; Wiley, USA, 3<sup>rd</sup> Edition, 1995, p.1-2] supplemented with 0.2% glucose, 40  $\mu$ g/ml isoleucine, 40  $\mu$ g/ml valine, 100  $\mu$ g/ml ampicillin and with or without nucleoside analogues.

For the first screening 200  $\mu$ l of 2.5 mM AraC, 500  $\mu$ M AZT, 500  $\mu$ M ddA or 25 mM ddC were evenly spread on the surface of a 10 ml solidified medium containing 8.5 cm diameter plate. Growth of colonies was visually inspected after 24 hours at 37°C. From clones not growing on nucleoside analogue containing plates,

but growing normally on plates without the nucleoside analogue, the plasmid was isolated and re-transformed into KY895. These clones were re-tested to verify the plasmid born phenotype.

## 5 Example 2

### Characterisation of the Enzyme Variants

#### Sequencing

Sequencing by the Sanger dideoxynucleotide method was performed  
10 manually, using the Thermo Sequenase radio-labelled terminator cycle sequencing kit  
and P<sup>33</sup> labelled ddNTPs (Amersham Corp.) on the purified plasmids.

#### Determination of LD<sub>100</sub> (*in vivo* characterisation)

All clones with increased sensitivity towards at least one nucleoside  
15 analogue were tested on M9 plates with logarithmic dilution of the nucleoside  
analogues to determine the lethal dose (LD<sub>100</sub>) of the nucleoside analogues, at which  
no growths of bacteria could be seen. Plates with the concentration ranges 10 - 1000  
μM of AraA, 3.16 - 1000 μM of AraC; 0.01 - 100 μM of AZT; 0.316 - 31.6 μM of ddA;  
0.0316 - 100 μM of 2CdA or 10 - 3500 μM of ddC; were used to determine the LD<sub>100</sub>  
20 (the concentrations which cause 100% lethality) of putative mutants.

Plates were prepared by mixing the medium with the analogues at the  
lowest temperature possible, before pouring the plates.

The results of these tests are presented in Table 2, below.

Table 2  
LD<sub>100</sub>

Amino acid position	51	62	91	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	1481	1482	1483	1484	1485	1486	1487	1488	1489	1490	1491	1492	1493	1494	1495	1496	1497	1498	1499	1500	1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515	1516	1517	1518	1519	1520	1521	1522	1523	1524	1525	1526	1527	1528	1529	1530	1531	1532	1533	1534	1535	1536	1537	1538	1539	1540	1541	1542	1543	1544	1545	1546	1547	1548	1549	1550	15
---------------------	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	----

[illegible]

### Protein expression and purification (*in vitro* characterisation)

Higher expression was obtained in *E. coli* strain BL21 (Pharmacia Biotech, Sweden) than in KY895 cells. Expression and purification of thrombin cleaved recombinant wild-type *Dm*-dNK or mutant MuD was done as described by Munch-Petersen *et al.* [*J. Biol. Chem.* 2000 **275** (9) 6673-6679]. Purified proteins are referred to as r*Dm*-dNK or rMuD.

### Enzyme assays

Nucleoside kinase activities were determined by initial velocity measurements based on four time samples by the DE-81 filter paper assay using tritium-labelled substrates. Alternatively ADP production was measured by a spectrometric assay. Both assays were done as described by Munch-Petersen *et al.* [*J. Biol. Chem.* 2000 **275** (9) 6673-6679].

### Analysis of Kinetic Data

Kinetic data were evaluated as described in Knecht *et al.* [Knecht W, Bergjohann U, Gonski S, Kirschbaum B, Löffler M: Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme; *Eur. J. Biochem.* 1996 **240** (1) 292-301] by non-linear regression analysis using the Michaelis-Menten equation  $v = V_{\max} \times [S]/(K_m + [S])$ .

Concentrations giving 50 % inhibition of enzyme activity ( $IC_{50}$ ) were determined by fitting the equation  $v_i = v_0/(1 + [I]/IC_{50})$  to the velocities of the reaction in the presence of varying inhibitor concentrations [I].  $v_i$  and  $v_0$  are the velocities in presence or absence of inhibitor, respectively.

To determine the type of inhibition,  $V_{\max}$  and  $K_m$  values were determined at 3 different inhibitor concentrations. Deviations of  $V_{\max}$  and  $K_m$  values in comparison with the constants for the non-inhibited enzymatic reaction were considered to determine whether the inhibition was competitive, un-competitive or non-competitive.

Once an inhibition pattern was established, the unchanged equation for non-competitive inhibition  $v = V_{\max} \times [S]/\{K_m \times (1 + [I]/K_{ic}) + (1 + [I]/K_{iu}) \times [S]\}$  was fit the entire data set.  $K_{ic}$  is the competitive inhibition constant,  $K_{iu}$  is the un-competitive inhibition constant [Liebecg C: IUBMB Biochemical nomenclature and related documents; Portland Press, London, 1992].

**Example 3****Sequence Determination**

The Basic local alignment search tool (BLAST) was used to search the publically available expressed sequence tag (EST) libraries in the GenBank database at the National Institute for Biotechnology information and to identify ESTs that encode enzymes similar to *Dm*-dNK (GenBank ACCN AF226281). In this way the ESTs ACCN AU004911 from *Bombyx mori* and ACCN AW159435 from *Xenopus laevis* were identified.

The ESTs were obtained from the Genome Research Group, National Institute of Radiological Sciences, Anagawa 4-9-1, Inage, Chiba 263-8555, Japan (ACCN AU004911) and from Lita Annenberg Hazen Genome Sequencing Center, Cold Spring Harbor Laboratory, PO Box 100, Cold Spring Harbor, NY 11724, USA (AW159435). The complete open reading frame of the deoxyribonucleoside kinases encoded by these two ESTs was determined by DNA sequencing (see Example 2).

The complete open reading frames were then submitted to GenBank and received assignments ACCN AF226281 (*Bombyx mori* deoxyribonucleoside kinase, presented as SEQ ID NO: 3) and ACCN AF250861 (*Xenopus laevis* deoxyribonucleoside kinase, presented as SEQ ID NO: 5).

**Example 4****Hybrid Enzymes**

This example described the construction of hybrid enzymes in the expression vector pGEX-2T (pGEX-2T-rdmk/bmk and pGEX-2T-rbmk/dmk, respectively).

The expression plasmid pGEX-2T-r*Bm*-dNK was constructed essentially as described by Munch-Petersen et al. [Munch-Petersen et al., *J. Biol. Chem.* 2000 **275** (9) 6673-6679] for pGEX-2T-r*Dm*-dNK using the primers *Bm*<sub>for</sub>1 and *Bm*<sub>rev</sub>1, and the cDNA for *Bombyx mori* kinase, obtained as described in Example 3, as template.

The following 1<sup>th</sup> PCR's were done:

30

	bmk/dmk 1	bmk/dmk 2	dmk/bmk 1	dmk/bmk 2
Primer 1	pGEX-2T <sub>for</sub>	pGEX-2T <sub>rev</sub>	pGEX-2T <sub>for</sub>	pGEX-2T <sub>rev</sub>
Primer 2	bmk-N <sub>term</sub>	dmk-C <sub>term</sub>	dmk-N <sub>term</sub>	bmk-C <sub>term</sub>
Template	pGEX-2T-r <i>Bm</i> -dNK	pGEX-2T-r <i>Dm</i> -dNK	pGEX-2T-r <i>Dm</i> -dNK	pGEX-2T-r <i>Bm</i> -dNK

The PCR conditions were: Denaturation at 94°C for 5 minutes, 30 times cycling at 94°C for 1 minute, 50°C for 1 minute and 72°C for 1 minute, and final prolongation for 10 minutes at 72°C.

The resulting fragments from all four PCR's were purified by the PCR  
5 Purification Kit from Boehringer Mannheim.

Then the following 2<sup>nd</sup> PCR's were done:

	bmk/dmk	dmk/bmk
Primer 1	<i>Bm<sub>for</sub></i> 1	<i>Dm</i> -TK3 (SEQ ID NO: 7)
Primer 2	<i>Dm</i> -TK4 (SEQ ID NO: 8)	<i>Bm<sub>rev</sub></i> 1
Template	bmk/dmk 1 and bmk/dmk 2 from the 1 <sup>th</sup> PCR	dmk/bmk 1 and dmk/bmk 2

The PCR conditions were: Denaturation at 94°C for 5 minutes, 30 times  
10 cycling at 94°C for 1 minute, 45°C for 5 minutes and 72°C for 1 minute, and final  
prolongation for 10 minutes at 72°C.

The resulting fragments were cut, purified and subcloned into the  
expression vector obtained as described under Example 1.

#### 15 Primers

*Dm*-TK3 (SEQ ID NO: 7);

*Dm*-TK4 (SEQ ID NO: 8);

pGEX-2T<sub>for</sub>: 5'- acg ttt ggt ggt ggc gac ca -3' (SEQ ID NO: 13);

pGEX-2T<sub>rev</sub>: 5'- ctc cgg gag ctg cat gtg tc -3' (SEQ ID NO: 14);

20 bmk-N<sub>term</sub>: 5'- cta aaa atg gag cgc tcc att agc ttt act gga gtt gg -3' (SEQ ID NO: 15);

dmk-C<sub>term</sub>: 5'- cca gta aag cta atg gag cgc tcc att ttt agc gc -3' (SEQ ID NO: 16);

dmk-N<sub>term</sub>: 5'- gaa taa tga tcg ctc cat tat ttt tag ctt ctt gt -3' (SEQ ID NO: 17);

bmk-C<sub>term</sub>: 5'- aag cta aaa ata atg gag cga tca tta ttc agt gc -3' (SEQ ID NO: 18);

*Bm<sub>for</sub>*1: 5'- tat cgc gga tcc atg agt gcc aac aat gtt aaa cca ttc acc -3' (SEQ ID NO: 19);

25 and

*Bm<sub>rev</sub>*1: 5'- ccg gaa ttc gtc gac tta taa gat cct cat gtg agg tgt gat ctt g -3' (SEQ ID NO: 20).

**CLAIMS:**

1. An isolated, mutated polynucleotide encoding a multi-substrate deoxyribonucleoside kinase enzyme, which mutated polynucleotide, when compared to the non-mutated polynucleotide, and upon transformation into a bacterial or eukaryotic cell, decreases at least 4 fold the lethal dose ( $LD_{100}$ ) of at least one nucleoside analogue.
2. The mutated polynucleotide of claim 1, wherein said nucleoside analogue is aciclovir (9-[2-hydroxy-ethoxy]-methyl-guanosine), buciclovir, famciclovir, ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]-guanosine), penciclovir, valciclovir, trifluorothymidine, AZT (3'-azido-3'-thymidine), AIU (5'-iodo-5'-amino-2',5'-dideoxyuridine), ara-A (adenosine-arabinoside; Vivarabine), ara-C (cytidine-arabinoside), ara-G (9-beta-D-arabinofuranosylguanine), ara-T, 1-beta-D-arabinofuranosyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2,5'-dideoxyuridine, 1-[2-deoxy-2-fluoro-beta-D-arabino furanosyl]-5-iodouracil, idoxuridine (5-iodo-2'-deoxyuridine), fludarabine (2-Fluoroadenine 9-beta-D-Arabinofuranoside), gencitabine, 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), 2',3'-dideoxythymidine (ddT), 2',3'-dideoxyadenosine (ddA), 2',3'-dideoxyguanosine (ddG), 2-chloro-2'-deoxyadenosine (2CdA), 5-fluorodeoxyuridine, BVaraU ((E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil), BVDU (5-bromovinyl-deoxyuridine), FIAU (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil), 3TC (2'-deoxy-3'-thiacytidine), dFdC gemcitabine (2',2'-difluorodeoxycytidine), dFdG (2',2'-difluorodeoxyguanosine), or d4T (2',3'-didehydro-3'-deoxythymidine).
3. The mutated polynucleotide of claim 1, which mutated polynucleotide, decreases at least 4 fold the lethal dose ( $LD_{100}$ ) of at least two different nucleoside analogues, which analogues are based on two different sugar moieties and two different base moieties.
4. An isolated deoxyribonucleoside kinase variant encoded by the polynucleotide of claims 1-3.
5. The enzyme variant of claim 4, which variant is altered with respect to
  - (i) The ratio " $k_{cat}/K_m(\text{substrate}) / k_{cat}/K_m(\text{nucleoside analogue})$ " is decreased by at least at least 5 fold; and/or



- (ii) The feedback inhibition by NTP's and dNTPs, in particular TTP, is decreased by at least 1.5 fold, as determined by its IC<sub>50</sub> value using 2 or 10  $\mu$ M thymidine (dThd) as a substrate;  
when compared to the wild-type enzyme.
- 5
6. The enzyme variant of claim 4, which decreases at least 4 fold the lethal dose (LD<sub>100</sub>) of at least two different nucleoside analogues, which analogues are based on two different sugar moieties and two different base moieties.
- 10 7. The enzyme variant of claim 4, which variant, when compared to the wild-type enzyme, has been mutated in
- (i) in a non-motif and/or a non-conserved region; and/or
  - (ii) in only one motif and/or conserved region; and/or
  - (iii) in any conserved position;
- 15 the regions and positions being as defined in Table 1.
8. The enzyme variant of claim 4, which variant comprises a mutation (incl. substitutions, additions and deletions) at one or more of the following positions 51, 62, 82, 91, 100, 102, 107, 112, 114, 134, 138, 139, 140, 164, 167, 168, 171, 199, 202, 207; 211, 213; 214, 216, 217, 220, 222, 228, 229, 274, 277, 281, 283; 284; 307, 309, 316, 318, 321, 334, 347, and 352 (dNK numbering).
- 20
9. The enzyme variant of claim 6, which variant comprises a substitution conservative to those of G80, N81, I82, G83, S84, G85, K86, T87, T88, E107, P108, V109, E110, K111, W112, Y140, Q164, E201, R202, S203, C210, Y211, C212, P258, R265, I266, R267, Q268, R269, A270, R271, E274, L279, L282, or L293 (dNK numbering).
- 25
10. The enzyme variant of claim 6, which variant comprises one or more of the following mutations M51T; T62A; N91D; N100D; I102T; N114D; N134D; N134S; L138S; M139L; M139V; V167A; V167S; V167M; T168A; M171R; I199M; A207D; V214A; N216S; M217V; N220S; S222W; Y228C; N229S; V277A; Y281H; S307P; K309R; D316N; N318D; N321S; F334L; L347P; and K352N (dNK numbering).
- 30
11. The enzyme variant of claim 8, which variant comprises
- M51T/T168A/N220S;
  - T62A/V167A/N321S;
- 35

N91D/N134D;  
 N100D/N134D;  
 N100D/N134D/N318D/L347P;  
 N100D/N134D/I199M/N216S/M217V/D316N;  
 5 I102T/N318D;  
 N114D/M217V/Y281H;  
 N134S/L138S/M139L/K352N;  
 M139V/N318D/L347P;  
 V167A/M171R/A207D;  
 10 V167S/M171R/A207D;  
 V167A/I199M/N216S/M217V/D316N;  
 V167A/N318D/L347P;  
 T168A/N318D/L347P;  
 T168A/I199M/N216S/M217V/D316N;  
 15 M171R/A207D;  
 I199M/V214A/N216S/M217V/D316N;  
 I199M/N216S/M217V/N229S/S307P/D316N;  
 I199M/N216S/M217V/D316N;  
 S222W/F334L;  
 20 Y228C/V277A/K309R; or  
 N318D/L347P (dNK numbering).

12. The enzyme variant of any of claims 3-9, which variant is derived from a multi-substrate deoxyribonucleoside kinase.
- 25 13. The enzyme variant of any of claims 3-9, which variant is a deoxyribonucleoside kinase derived from a human thymidine kinase 2 (hu-TK2); or a human deoxyguanosine kinase (hu-dGK); or a human deoxycytidine kinase (hu-dCK); or a Herpes simplex virus thymidine kinase (HSV1-TK).
- 30 14. The enzyme variant of any of claims 3-9, which variant is derived from an insect multi-substrate deoxyribonucleoside kinase.
15. The enzyme variant of claim 14, which is a hybrid deoxyribonucleoside kinase  
 35 derived from two or more insect multi-substrate deoxyribonucleoside kinases.

16. The enzyme variant of claim 15, which hybrid deoxyribonucleoside kinase comprises at least 5 consecutive amino acids derived from each insect multi-substrate deoxyribonucleoside kinases.
- 5 17. The enzyme variant of claim 14, which variant is a deoxyribonucleoside kinase derived from a *Drosophila melanogaster* deoxyribonucleoside kinase (*Dm*-dNK), or a *Bombyx mori* deoxyribonucleoside kinase (*Bm*-dNK), or a *Xenopus laevis* deoxyribonucleoside kinase (*Xen*-dNK), or an *Anopheles gambia* deoxyribonucleoside kinase.
- 10 18. The enzyme variant of claim 17 being
- Dm*-dNK/M51T;
- Dm*-dNK/M51T/T168A/N220S;
- Dm*-dNK/T62A;
- 15 *Dm*-dNK/T62A/V167A/N321S;
- Dm*-dNK/N91D;
- Dm*-dNK/N91D/N134D;
- Dm*-dNK/N100D;
- Dm*-dNK/N100D/N134D;
- 20 *Dm*-dNK/N100D/N134D/N318D/L347P;
- Dm*-dNK/N100D/N134D/I199M/N216S/M217V/D316N;
- Dm*-dNK/I102T;
- Dm*-dNK/I102T/N318D;
- Dm*-dNK/N114D;
- 25 *Dm*-dNK/N114D/M217V/Y281H;
- Dm*-dNK/N134D;
- Dm*-dNK/N134S;
- Dm*-dNK/N134S/L138S/M139L/K352N;
- Dm*-dNK/L138S;
- 30 *Dm*-dNK/M139L;
- Dm*-dNK/M139V;
- Dm*-dNK/M139V/N318D/L347P;
- Dm*-dNK/V167A;
- Dm*-dNK/V167A/I199M/N216S/M217V/D316N;
- 35 *Dm*-dNK/V167A/N318D/L347P;
- Dm*-dNK/V167A/M171R/A207D;
- Dm*-dNK/V167S/M171R/A207D;
- Dm*-dNK/T168A;

35

*Dm*-dNK/T168A/N318D/L347P;  
*Dm*-dNK/T168A/I199M/N216S/M217V/D316N;  
*Dm*-dNK/ M171R/A207D;  
*Dm*-dNK/I199M;  
5 *Dm*-dNK/I199M/V214A/N216S/M217V/D316N;  
*Dm*-dNK/I199M/N216S/M217V/D316N;  
*Dm*-dNK/I199M/N216S/M217V/N229S/S307P/D316N;  
*Dm*-dNK/V214A;  
*Dm*-dNK/N216S;  
10 *Dm*-dNK/M217V;  
*Dm*-dNK/N220S;  
*Dm*-dNK/S222W;  
*Dm*-dNK/S222W/F334L;  
*Dm*-dNK/Y228C;  
15 *Dm*-dNK/Y228C/V277A/K309R;  
*Dm*-dNK/N229S;  
*Dm*-dNK/V277A;  
*Dm*-dNK/Y281H;  
*Dm*-dNK/S307P;  
20 *Dm*-dNK/K309R;  
*Dm*-dNK/D316N;  
*Dm*-dNK/N318D;  
*Dm*-dNK/N318D/L347P;  
*Dm*-dNK/N321S;  
25 *Dm*-dNK/F334L;  
*Dm*-dNK/L347P; or  
*Dm*-dNK/K352N (dNK numbering).

19. The enzyme variant of claim 17 being

30 *Bm*-dNK/E91D;  
*Bm*-dNK/E91D/N134D;  
*Bm*-dNK/-100D;  
*Bm*-dNK/-100D/N134D;  
*Bm*-dNK/-100D/N134D/K347P;  
35 *Bm*-dNK/-100D/N134D/L199M/H216S/I217V/D316N;  
*Bm*-dNK/I102T;  
*Bm*-dNK/N114D;  
*Bm*-dNK/N114D/I217V/Y281H;

*Bm*-dNK/N134D;  
*Bm*-dNK/N134S;  
*Bm*-dNK/N134S/L138S/M139L/K352N;  
*Bm*-dNK/L138S;  
5 *Bm*-dNK/M139L;  
*Bm*-dNK/M139V;  
*Bm*-dNK/M139V/K347P;  
*Bm*-dNK/V167A;  
*Bm*-dNK/ V167A/M171R/A207D;  
10 *Bm*-dNK/ V167S/M171R/A207D;  
*Bm*-dNK/V167A/L199M/H216S/I217V/D316N;  
*Bm*-dNK/V167A/Q321S;  
*Bm*-dNK/V167A/K347P;  
*Bm*-dNK/S168A;  
15 *Bm*-dNK/S168A/L199M/H216S/I217V/D316N;  
*Bm*-dNK/S168A/N220S;  
*Bm*-dNK/S168A/K347P;  
*Bm*-dNK/L199M;  
*Bm*-dNK/L199M/H216S/I217V/D316N;  
20 *Bm*-dNK/L199M/V214A/H216S/I217V/D316N;  
*Bm*-dNK/I199M/H216S/I217V/A229S/D316N;  
*Bm*-dNK/ M171R/A207D;  
*Bm*-dNK/V214A;  
*Bm*-dNK/H216S;  
25 *Bm*-dNK/I217V;  
*Bm*-dNK/N220S;  
*Bm*-dNK/T222W;  
*Bm*-dNK/F228C;  
*Bm*-dNK/F228C/V277A/P309R;  
30 *Bm*-dNK/V277A;  
*Bm*-dNK/A229S;  
*Bm*-dNK/Y281H;  
*Bm*-dNK/P309R;  
*Bm*-dNK/D316N;  
35 *Bm*-dNK/Q321S;  
*Bm*-dNK/L334L;  
*Bm*-dNK/K347P; or  
*Bm*-dNK/K352N (dNK numbering).

20. The enzyme variant of claim 17 being
- Xen*-dNK/M51T;
  - Xen*-dNK/M51T/Q168A;
  - 5 *Xen*-dNK/G62A;
  - Xen*-dNK/G62A/V167A/E321S;
  - Xen*-dNK/-100D;
  - Xen*-dNK/-100D/N134D;
  - Xen*-dNK/-100D/N134D/E318D;
  - 10 *Xen*-dNK/-100D/N134D/N216S/L217V;
  - Xen*-dNK/L102T;
  - Xen*-dNK/L102T/E318D;
  - Xen*-dNK/N114D;
  - Xen*-dNK/N114D/L217V/Y281H;
  - 15 *Xen*-dNK/N134D;
  - Xen*-dNK/N134S;
  - Xen*-dNK/N134S/L138S/M139L;
  - Xen*-dNK/L138S;
  - Xen*-dNK/M139L;
  - 20 *Xen*-dNK/M139V;
  - Xen*-dNK/M139V/E318D/;
  - Xen*-dNK/V167A;
  - Xen*-dNK/ V167A/M171R/A207D;
  - Xen*-dNK/ V167S/M171R/A207D;
  - 25 *Xen*-dNK/V167A/N216S/L217V;
  - Xen*-dNK/V167A/E318D;
  - Xen*-dNK/Q168A;
  - Xen*-dNK/Q168A/N216S/L217V;
  - Xen*-dNK/Q168A/E318D;
  - 30 *Xen*-dNK/ M171R/A207D;
  - Xen*-dNK/V214A;
  - Xen*-dNK/V214A/N216S/L217V;
  - Xen*-dNK/N216S;
  - Xen*-dNK/N216S/L217V;
  - 35 *Xen*-dNK/N216S/L217V/A229S;
  - Xen*-dNK/L217V;
  - Xen*-dNK/K222W;
  - Xen*-dNK/Y228C;

*Xen*-dNK/Y228C/I277A/P309R;  
*Xen*-dNK/A229S;  
*Xen*-dNK/I277A;  
*Xen*-dNK/Y281H;  
5 *Xen*-dNK/P309R;  
*Xen*-dNK/E318D; or  
*Xen*-dNK/E321S (dNK numbering).

21. The enzyme variant of claim 16, being a hybrid enzyme derived from a  
10 *Drosophila melanogaster* deoxyribonucleoside kinase, and/or a *Bombyx mori*  
deoxyribonucleoside kinase, and/or a *Xenopus laevis* deoxyribonucleoside  
kinase, and/or an *Anopheles gambia* deoxyribonucleoside kinase.
22. The enzyme variant of claim 21, which is derived from a *Drosophila*  
15 *melanogaster* deoxyribonucleoside kinase and a *Bombyx mori*  
deoxyribonucleoside kinase, and which comprises the amino acid sequence  
presented as SEQ ID NO: 10.
23. The enzyme variant of claim 21, which is derived from a *Drosophila*  
20 *melanogaster* deoxyribonucleoside kinase and a *Bombyx mori*  
deoxyribonucleoside kinase, and which comprises the amino acid sequence  
presented as SEQ ID NO: 12.
24. A vector construct comprising the polynucleotide according to any of claims 1-3.  
25
25. The vector according to claim 24 being a viral vector, in particular a herpes  
simplex viral vector, an adenoviral vector, an adenovirus-associated viral vector,  
or a retroviral vector.
- 30 26. A packaging cell line capable of producing an infective virion comprising the  
vector of claim 25.
27. A host cell carrying the mutated polynucleotide according to any of claims 1-3,  
or the vector according to either of claims 24-25.
- 35 28. The cell according to claim 27, which is a human cell, a dog cell, a monkey cell,  
a rat cell or a mouse cell.

29. A method of sensitising a cell to a prodrug, which method comprises the steps of
- (i) transfecting said cell with a polynucleotide sequence according to any of claims 1-3 encoding an enzyme that promotes the conversion of said prodrug into a (cytotoxic) drug; and
  - (ii) delivering said prodrug to said cell;
- wherein said cell is more sensitive to said (cytotoxic) drug than to said prodrug.
30. The method according to claim 29, wherein the prodrug is a nucleoside analogue.
31. The method according to claim 30, wherein the nucleoside analogue is aciclovir (9-[2-hydroxy-ethoxy]-methyl-guanosine), buciclovir, famciclovir, ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]-guanosine), penciclovir, valciclovir, trifluorothymidine, AZT (3'-azido-3'-thymidine), AIU (5'-iodo-5'-amino-2',5'-dideoxyuridine), ara-A (adenosine-arabinoside; Vivarabine), ara-C (cytidine-arabinoside), ara-G (9-beta-D-arabinofuranosylguanine), ara-T, 1-beta-D-arabinofuranosyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2',5'-dideoxyuridine, 1-[2-deoxy-2-fluoro-beta-D-arabino furanosyl]-5-iodouracil, idoxuridine (5-iodo-2'-deoxyuridine), fludarabine (2-Fluoroadenine 9-beta-D-Arabinofuranoside), gencitabine, 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), 2',3'-dideoxythymidine (ddT), 2',3'-dideoxyadenosine (ddA), 2',3'-dideoxyguanosine (ddG), 2-chloro-2'-deoxyadenosine (2CdA), 5-fluorodeoxyuridine, BVaraU ((E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil), BVDU (5-bromovinyl-deoxyuridine), FIAU (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil), 3TC (2'-deoxy-3'-thiacytidine), dFdC gemcitabine (2',2'-difluorodeoxycytidine), dFdG (2',2'-difluorodeoxyguanosine), or d4T (2',3'-didehydro-3'-deoxythymidine).
32. A method of inhibiting a pathogenic agent in a warm-blooded animal, which method comprises administering to said animal a mutated polynucleotide according to any of claims 1-3, or a vector according to either of claims 24-25.
33. The method according to claim 32, wherein said polynucleotide sequence or said vector is administered *in vivo*.
34. The method according to either of claims 32-33, wherein said pathogenic agent is a virus, a bacteria or a parasite.



35. The method according to either of claims 32-33, wherein said pathogenic agent is a tumour cell.
- 5 36. The method according to either of claims 32-33, wherein said pathogenic agent is an autoreactive immune cell.
37. The method according to any of claims 31-35, further comprising the step of administering a nucleoside analogue to said warm-blooded animal.
- 10 38. The method according to claim 37, wherein said nucleoside analogue is aciclovir (9-[2-hydroxy-ethoxy]-methyl-guanosine), buciclovir, famciclovir, ganciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]-guanosine), penciclovir, valciclovir, trifluorothymidine, AZT (3'-azido-3'-thymidine), AIU (5'-iodo-5'-amino-2',5'-dideoxyuridine), ara-A (adenosine-arabinoside; Vivarabine), ara-C (cytidine-arabinoside), ara-G (9-beta-D-arabinofuranosylguanine), ara-T, 1-beta-D-arabinofuranosyl thymine, 5-ethyl-2'-deoxyuridine, 5-iodo-5'-amino-2,5'-dideoxyuridine, 1-[2-deoxy-2-fluoro-beta-D-arabino furanosyl]-5-iodouracil, idoxuridine (5-iodo-2'-deoxyuridine), fludarabine (2-Fluoroadenine 9-beta-D-Arabinofuranoside), gencitabine, 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), 2',3'-dideoxythymidine (ddT), 2',3'-dideoxyadenosine (ddA), 2',3'-dideoxyguanosine (ddG), 2-chloro-2'-deoxyadenosine (2CdA), 5-fluorodeoxyuridine, BVaraU ((E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil), BVDU (5-bromovinyl-deoxyuridine), FIAU (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil), 3TC (2'-deoxy-3'-thiacytidine), dFdC gemcitabine (2',2'-difluorodeoxycytidine), dFdG (2',2'-difluorodeoxyguanosine), or d4T (2',3'-didehydro-3'-deoxythymidine).
- 20 39. A pharmaceutical composition comprising a mutated polynucleotide according to any of claims 1-3, or a vector according to either of claims 24-25.
- 30 40. A pharmaceutical composition comprising the enzyme variant according to any of claims 4-23, and a pharmaceutically acceptable carrier or diluent.

1/2




Fig. 1

2/2




Fig. 2

## SEQUENCE LISTING

<160> 20  
 <170> PatentIn Ver. 2.1  
  
 <210> 1  
 <211> 750  
 <212> DNA  
 <213> *Drosophila melanogaster*  
  
 <220>  
 <221> CDS  
 <222> (1)..(750)  
  
 <400> 1  
 atg gcg gag gca gca tcc tgt gcc cga aag ggg acc aag tac gcc gag 48  
 Met Ala Glu Ala Ala Ser Cys Ala Arg Lys Gly Thr Lys Tyr Ala Glu  
   1                  5                  10                  15  
  
 ggc acc cag ccc ttc acc gtc ctc atc gag ggc aac atc ggc agc ggg 96  
 Gly Thr Gln Pro Phe Thr Val Leu Ile Glu Gly Asn Ile Gly Ser Gly  
                   20                  25                  30  
  
 aag acc acg tat ttg aac cac ttc gag aag tac aag aac gac att tgc 144  
 Lys Thr Thr Tyr Leu Asn His Phe Glu Lys Tyr Lys Asn Asp Ile Cys  
           35                  40                  45  
  
 ctg ctg acc gag ccc gtc gag aag tgg cgc aac gtc aac ggg gta aat 192  
 Leu Leu Thr Glu Pro Val Glu Lys Trp Arg Asn Val Asn Gly Val Asn  
   50                  55                  60  
  
 ctg ctg gag ctg atg tac aaa gat ccc aag aag tgg gcc atg ccc ttt 240  
 Leu Leu Glu Leu Met Tyr Lys Asp Pro Lys Lys Trp Ala Met Pro Phe  
   65                  70                  75                  80  
  
 cag agt tat gtc acg ctg acc atg ctg cag tgc cac acc gcc cca acc 288  
 Gln Ser Tyr Val Thr Leu Thr Met Leu Gln Ser His Thr Ala Pro Thr  
           85                  90                  95  
  
 aac aag aag cta aaa ata atg gag cgc tcc att ttt agc gct cgc tat 336  
 Asn Lys Lys Leu Lys Ile Met Glu Arg Ser Ile Phe Ser Ala Arg Tyr  
          100                 105                 110  
  
 tgc ttc gtg gag aac atg cga cga aac ggc tgc ctg gag cag ggc atg 384  
 Cys Phe Val Glu Asn Met Arg Arg Asn Gly Ser Leu Glu Gln Gly Met  
          115                 120                 125  
  
 tac aat acg ctg gag gag tgg tac aag ttc atc gaa gag tcc att cac 432  
 Tyr Asn Thr Leu Glu Glu Trp Tyr Lys Phe Ile Glu Glu Ser Ile His  
   130                 135                 140  
  
 gtg cag gcg gac ctc atc ata tat ctg cgc acc tgc ccg gag gtg gcg 480  
 Val Gln Ala Asp Leu Ile Ile Tyr Leu Arg Thr Ser Pro Glu Val Ala  
  145                 150                 155                 160  
  
 tac gaa cgc atc cgg cag cgg gct cgt tct gag gag agc tgc gtg ccg 528  
 Tyr Glu Arg Ile Arg Gln Arg Ala Arg Ser Glu Glu Ser Cys Val Pro  
          165                 170                 175  
  
 ctt aag tac ctt cag gag ctg cat gag ttg cac gag gac tgg ttg ata 576  
 Leu Lys Tyr Leu Gln Glu Leu His Glu Leu His Glu Asp Trp Leu Ile  
          180                 185                 190

## 2

```

cac cag aga cga ccg cag tcg tgc aag gtc cta gtc ctc gat gcc gat 624
His Gln Arg Arg Pro Gln Ser Cys Lys Val Leu Val Leu Asp Ala Asp
      195                200                205

ctg aac ctg gaa aac att ggc acc gag tac cag cgc tcg gag agc agc 672
Leu Asn Leu Glu Asn Ile Gly Thr Glu Tyr Gln Arg Ser Glu Ser Ser
      210                215                220

ata ttc gac gcc atc tca agt aac caa cag ccc tcg ccg gtt ctg gtg 720
Ile Phe Asp Ala Ile Ser Ser Asn Gln Gln Pro Ser Pro Val Leu Val
      225                230                235                240

tcg ccc agc aag cgc cag agg gtc gcc aga 750
Ser Pro Ser Lys Arg Gln Arg Val Ala Arg
      245                250

```

```

<210> 2
<211> 250
<212> PRT
<213> Drosophila melanogaster

```

```

<400> 2
Met Ala Glu Ala Ala Ser Cys Ala Arg Lys Gly Thr Lys Tyr Ala Glu
  1                5                10                15

Gly Thr Gln Pro Phe Thr Val Leu Ile Glu Gly Asn Ile Gly Ser Gly
      20                25                30

Lys Thr Thr Tyr Leu Asn His Phe Glu Lys Tyr Lys Asn Asp Ile Cys
      35                40                45

Leu Leu Thr Glu Pro Val Glu Lys Trp Arg Asn Val Asn Gly Val Asn
      50                55                60

Leu Leu Glu Leu Met Tyr Lys Asp Pro Lys Lys Trp Ala Met Pro Phe
      65                70                75                80

Gln Ser Tyr Val Thr Leu Thr Met Leu Gln Ser His Thr Ala Pro Thr
      85                90                95

Asn Lys Lys Leu Lys Ile Met Glu Arg Ser Ile Phe Ser Ala Arg Tyr
      100                105                110

Cys Phe Val Glu Asn Met Arg Arg Asn Gly Ser Leu Glu Gln Gly Met
      115                120                125

Tyr Asn Thr Leu Glu Glu Trp Tyr Lys Phe Ile Glu Glu Ser Ile His
      130                135                140

Val Gln Ala Asp Leu Ile Ile Tyr Leu Arg Thr Ser Pro Glu Val Ala
      145                150                155                160

Tyr Glu Arg Ile Arg Gln Arg Ala Arg Ser Glu Glu Ser Cys Val Pro
      165                170                175

Leu Lys Tyr Leu Gln Glu Leu His Glu Leu His Glu Asp Trp Leu Ile
      180                185                190

His Gln Arg Arg Pro Gln Ser Cys Lys Val Leu Val Leu Asp Ala Asp
      195                200                205

```

## 3

Leu Asn Leu Glu Asn Ile Gly Thr Glu Tyr Gln Arg Ser Glu Ser Ser  
 210 215 220

Ile Phe Asp Ala Ile Ser Ser Asn Gln Gln Pro Ser Pro Val Leu Val  
 225 230 235 240

Ser Pro Ser Lys Arg Gln Arg Val Ala Arg  
 245 250

<210> 3  
 <211> 747  
 <212> DNA  
 <213> Bombyx mori

<220>  
 <221> CDS  
 <222> (1)..(747)

<400> 3  
 atg agt gcc aac aat gtt aaa cca ttc acc gtg ttc gtg gaa ggt aac 48  
 Met Ser Ala Asn Asn Val Lys Pro Phe Thr Val Phe Val Glu Gly Asn  
 1 5 10 15

ata ggt agc ggt aaa aca aca ttt ctg gaa cat ttt cgt cag ttt gag 96  
 Ile Gly Ser Gly Lys Thr Thr Phe Leu Glu His Phe Arg Gln Phe Glu  
 20 25 30

gat atc act ttg ttg acg gag ccc gtt gaa atg tgg cga gat ctt aaa 144  
 Asp Ile Thr Leu Leu Thr Glu Pro Val Glu Met Trp Arg Asp Leu Lys  
 35 40 45

ggt tgc aat ctt ttg gaa ctc atg tac aaa gat cca gaa aaa tgg gcg 192  
 Gly Cys Asn Leu Leu Glu Leu Met Tyr Lys Asp Pro Glu Lys Trp Ala  
 50 55 60

atg aca ttc cag tca tac gtt tcc ttg acg atg ttg gac atg cac cgg 240  
 Met Thr Phe Gln Ser Tyr Val Ser Leu Thr Met Leu Asp Met His Arg  
 65 70 75 80

aga cct gct cca act cca gta aag cta atg gag cga tca tta ttc agt 288  
 Arg Pro Ala Pro Thr Pro Val Lys Leu Met Glu Arg Ser Leu Phe Ser  
 85 90 95

gcg aga tac tgc ttc gtt gaa cac att atg aga aat aat aca ctc cat 336  
 Ala Arg Tyr Cys Phe Val Glu His Ile Met Arg Asn Asn Thr Leu His  
 100 105 110

cca gca cag ttt gca gta ctt gat gag tgg ttc cga ttc atc caa cac 384  
 Pro Ala Gln Phe Ala Val Leu Asp Glu Trp Phe Arg Phe Ile Gln His  
 115 120 125

aac att cct att gat gct gat ttg ata gta tat cta aag aca tca cct 432  
 Asn Ile Pro Ile Asp Ala Asp Leu Ile Val Tyr Leu Lys Thr Ser Pro  
 130 135 140

tca ata gtg tac caa agg ata aaa aag aga gct cgt tca gaa gag cag 480  
 Ser Ile Val Tyr Gln Arg Ile Lys Lys Arg Ala Arg Ser Glu Glu Gln  
 145 150 155 160

tgt gtg ccc ctg tca tac att gag gaa ctg cat agg ttg cat gag gac 528  
 Cys Val Pro Leu Ser Tyr Ile Glu Glu Leu His Arg Leu His Glu Asp  
 165 170 175

## 4

tgg cta atc aac agg ata cat gct gaa tgt ccc gca cca gta tta gtg 576  
 Trp Leu Ile Asn Arg Ile His Ala Glu Cys Pro Ala Pro Val Leu Val  
 180 185 190  
  
 tta gat gct gat tta gac ctc tct cag ata acc gat gaa tac aag aga 624  
 Leu Asp Ala Asp Leu Asp Leu Ser Gln Ile Thr Asp Glu Tyr Lys Arg  
 195 200 205  
  
 agt gag cat caa att tta aga aag gct gtt aat gta gtt atg agt tca 672  
 Ser Glu His Gln Ile Leu Arg Lys Ala Val Asn Val Val Met Ser Ser  
 210 215 220  
  
 cca aac aag cat agc cca aag aaa cca ata tca aca aca cca atc aag 720  
 Pro Asn Lys His Ser Pro Lys Lys Pro Ile Ser Thr Thr Pro Ile Lys  
 225 230 235 240  
  
 atc aca cct cac atg agg atc tta taa 747  
 Ile Thr Pro His Met Arg Ile Leu  
 245

<210> 4  
 <211> 248  
 <212> PRT  
 <213> Bombyx mori

<400> 4  
 Met Ser Ala Asn Asn Val Lys Pro Phe Thr Val Phe Val Glu Gly Asn  
 1 5 10 15  
  
 Ile Gly Ser Gly Lys Thr Thr Phe Leu Glu His Phe Arg Gln Phe Glu  
 20 25 30  
  
 Asp Ile Thr Leu Leu Thr Glu Pro Val Glu Met Trp Arg Asp Leu Lys  
 35 40 45  
  
 Gly Cys Asn Leu Leu Glu Leu Met Tyr Lys Asp Pro Glu Lys Trp Ala  
 50 55 60  
  
 Met Thr Phe Gln Ser Tyr Val Ser Leu Thr Met Leu Asp Met His Arg  
 65 70 75 80  
  
 Arg Pro Ala Pro Thr Pro Val Lys Leu Met Glu Arg Ser Leu Phe Ser  
 85 90 95  
  
 Ala Arg Tyr Cys Phe Val Glu His Ile Met Arg Asn Asn Thr Leu His  
 100 105 110  
  
 Pro Ala Gln Phe Ala Val Leu Asp Glu Trp Phe Arg Phe Ile Gln His  
 115 120 125  
  
 Asn Ile Pro Ile Asp Ala Asp Leu Ile Val Tyr Leu Lys Thr Ser Pro  
 130 135 140  
  
 Ser Ile Val Tyr Gln Arg Ile Lys Lys Arg Ala Arg Ser Glu Glu Gln  
 145 150 155 160  
  
 Cys Val Pro Leu Ser Tyr Ile Glu Glu Leu His Arg Leu His Glu Asp  
 165 170 175  
  
 Trp Leu Ile Asn Arg Ile His Ala Glu Cys Pro Ala Pro Val Leu Val  
 180 185 190

## 5

Leu Asp Ala Asp Leu Asp Leu Ser Gln Ile Thr Asp Glu Tyr Lys Arg  
 195 200 205

Ser Glu His Gln Ile Leu Arg Lys Ala Val Asn Val Val Met Ser Ser  
 210 215 220

Pro Asn Lys His Ser Pro Lys Lys Pro Ile Ser Thr Thr Pro Ile Lys  
 225 230 235 240

Ile Thr Pro His Met Arg Ile Leu  
 245

<210> 5  
 <211> 837  
 <212> DNA  
 <213> *Xenopus laevis*

<220>  
 <221> CDS  
 <222> (1)..(837)

<400> 5  
 atg tca gta cta cta gct gcc cgg aca tgt ata cgg ctc tgt tgt act 48  
 Met Ser Val Leu Leu Ala Ala Arg Thr Cys Ile Arg Leu Cys Cys Thr  
 1 5 10 15

gaa cat aaa aca ggc gct ctg gcg agg ttt aac ctc ggc gca aat act 96  
 Glu His Lys Thr Gly Ala Leu Ala Arg Phe Asn Leu Gly Ala Asn Thr  
 20 25 30

gcc ctg act gtt aga aga ata gcg agc gct ttg tgc ggc aga tgc aac 144  
 Ala Leu Thr Val Arg Arg Ile Ala Ser Ala Leu Cys Gly Arg Cys Asn  
 35 40 45

atc atg cgg aga gga ata ttg ccc tcg ggg agc aca ggt aat ggt cta 192  
 Ile Met Arg Arg Gly Ile Leu Pro Ser Gly Ser Thr Gly Asn Gly Leu  
 50 55 60

aaa agc cga gag aag agc aca gta att tgt gtg gag ggc aat att gca 240  
 Lys Ser Arg Glu Lys Ser Thr Val Ile Cys Val Glu Gly Asn Ile Ala  
 65 70 75 80

agt gga aaa aca agc tgc ttg gat tat ttt tct aat act cca gat ctt 288  
 Ser Gly Lys Thr Ser Cys Leu Asp Tyr Phe Ser Asn Thr Pro Asp Leu  
 85 90 95

gag gta ttc aag gag cct gta gct aaa tgg aga aat gtc tgt ggc cat 336  
 Glu Val Phe Lys Glu Pro Val Ala Lys Trp Arg Asn Val Cys Gly His  
 100 105 110

aac cca ctt ggt tta atg tat caa gat cct aac aag tgg ggc tta act 384  
 Asn Pro Leu Gly Leu Met Tyr Gln Asp Pro Asn Lys Trp Gly Leu Thr  
 115 120 125

ttg cag acg tac gtg caa ctc acc atg ttg gac att cac acc aaa cca 432  
 Leu Gln Thr Tyr Val Gln Leu Thr Met Leu Asp Ile His Thr Lys Pro  
 130 135 140

tca atc tcg cct gtt aaa atg atg gaa agg tca att tac agt gca aag 480  
 Ser Ile Ser Pro Val Lys Met Met Glu Arg Ser Ile Tyr Ser Ala Lys  
 145 150 155 160



## 6

tat atc ttt gta gag aac ttg tat cag agc gga aaa atg cca gcc gtg	528
Tyr Ile Phe Val Glu Asn Leu Tyr Gln Ser Gly Lys Met Pro Ala Val	
165 170 175	
gat tat gcc att tta aca gag tgg ttt aaa tgg att gta aag aac acc	576
Asp Tyr Ala Ile Leu Thr Glu Trp Phe Lys Trp Ile Val Lys Asn Thr	
180 185 190	
gat acc tcg gtt gat ctg atc gtt tat ctg cag aca tct cca gaa atc	624
Asp Thr Ser Val Asp Leu Ile Val Tyr Leu Gln Thr Ser Pro Glu Ile	
195 200 205	
tgt tac cag aga cta aag aag agg tgt aga gaa gag gag agt gtt ata	672
Cys Tyr Gln Arg Leu Lys Lys Arg Cys Arg Glu Glu Glu Ser Val Ile	
210 215 220	
cca ctg gaa tat ctg tgt gca atc cac aat ctc tat gaa gac tgg cta	720
Pro Leu Glu Tyr Leu Cys Ala Ile His Asn Leu Tyr Glu Asp Trp Leu	
225 230 235 240	
gtt aaa cag acg tcc ttc tca gtg ccg gca ccc gtg ctt gta ata gat	768
Val Lys Gln Thr Ser Phe Ser Val Pro Ala Pro Val Leu Val Ile Asp	
245 250 255	
ggg aat aaa gaa cta gag gaa ttg act caa cac tat gaa gag aat cgc	816
Gly Asn Lys Glu Leu Glu Glu Leu Thr Gln His Tyr Glu Glu Asn Arg	
260 265 270	
acc agc atc ttg tca ctg taa	837
Thr Ser Ile Leu Ser Leu	
275	

&lt;210&gt; 6

&lt;211&gt; 278

&lt;212&gt; PRT

<213> *Xenopus laevis*

&lt;400&gt; 6

Met Ser Val Leu Leu Ala Ala Arg Thr Cys Ile Arg Leu Cys Cys Thr	
1 5 10 15	
Glu His Lys Thr Gly Ala Leu Ala Arg Phe Asn Leu Gly Ala Asn Thr	
20 25 30	
Ala Leu Thr Val Arg Arg Ile Ala Ser Ala Leu Cys Gly Arg Cys Asn	
35 40 45	
Ile Met Arg Arg Gly Ile Leu Pro Ser Gly Ser Thr Gly Asn Gly Leu	
50 55 60	
Lys Ser Arg Glu Lys Ser Thr Val Ile Cys Val Glu Gly Asn Ile Ala	
65 70 75 80	
Ser Gly Lys Thr Ser Cys Leu Asp Tyr Phe Ser Asn Thr Pro Asp Leu	
85 90 95	
Glu Val Phe Lys Glu Pro Val Ala Lys Trp Arg Asn Val Cys Gly His	
100 105 110	
Asn Pro Leu Gly Leu Met Tyr Gln Asp Pro Asn Lys Trp Gly Leu Thr	
115 120 125	

## 7

Leu Gln Thr Tyr Val Gln Leu Thr Met Leu Asp Ile His Thr Lys Pro  
 130. 135 140  
 Ser Ile Ser Pro Val Lys Met Met Glu Arg Ser Ile Tyr Ser Ala Lys  
 145 150 155 160  
 Tyr Ile Phe Val Glu Asn Leu Tyr Gln Ser Gly Lys Met Pro Ala Val  
 165 170 175  
 Asp Tyr Ala Ile Leu Thr Glu Trp Phe Lys Trp Ile Val Lys Asn Thr  
 180 185 190  
 Asp Thr Ser Val Asp Leu Ile Val Tyr Leu Gln Thr Ser Pro Glu Ile  
 195 200 205  
 Cys Tyr Gln Arg Leu Lys Lys Arg Cys Arg Glu Glu Glu Ser Val Ile  
 210 215 220  
 Pro Leu Glu Tyr Leu Cys Ala Ile His Asn Leu Tyr Glu Asp Trp Leu  
 225 230 235 240  
 Val Lys Gln Thr Ser Phe Ser Val Pro Ala Pro Val Leu Val Ile Asp  
 245 250 255  
 Gly Asn Lys Glu Leu Glu Glu Leu Thr Gln His Tyr Glu Glu Asn Arg  
 260 265 270  
 Thr Ser Ile Leu Ser Leu  
 275

<210> 7  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: PCR primer  
 sequence

<400> 7  
 cgcggtatcca tggcggaggc agcatcct

28

<210> 8  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: PCR primer  
 sequence

<400> 8  
 cggaattctt atctggcgac cctctggcgt

30

<210> 9  
 <211> 711  
 <212> DNA  
 <213> hybrid

<220>  
 <221> CDS

## 8

&lt;222&gt; (1)..(711)

<223> 1-270 Bombyx mori; 271-711 Drosophila  
melanogaster.

&lt;400&gt; 9

atg agt gcc aac aat gtt aaa cca ttc acc gtg ttc gtg gaa ggt aac	48
Met Ser Ala Asn Asn Val Lys Pro Phe Thr Val Phe Val Glu Gly Asn	
1 5 10 15	
ata ggt agc ggt aaa aca aca ttt ctg gaa cat ttt cgt cag ttt gag	96
Ile Gly Ser Gly Lys Thr Thr Phe Leu Glu His Phe Arg Gln Phe Glu	
20 25 30	
gat atc act ttg ttg acg gag ccc gtt gaa atg tgg cga gat ctt aaa	144
Asp Ile Thr Leu Leu Thr Glu Pro Val Glu Met Trp Arg Asp Leu Lys	
35 40 45	
ggt tgc aat ctt ttg gaa ctc atg tac aaa gat cca gaa aaa tgg gcg	192
Gly Cys Asn Leu Leu Glu Met Tyr Lys Asp Pro Glu Lys Trp Ala	
50 55 60	
atg aca ttc cag tca tac gtt tcc ttg acg atg ttg gac atg cac cgg	240
Met Thr Phe Gln Ser Tyr Val Ser Leu Thr Met Leu Asp Met His Arg	
65 70 75 80	
aga cct gct cca act cca gta aag cta atg gag cgc tcc att ttt agc	288
Arg Pro Ala Pro Thr Pro Val Lys Leu Met Glu Arg Ser Ile Phe Ser	
85 90 95	
gct cgc tat tgc ttc gtg gag aac atg cga cga aac ggc tcg ctg gag	336
Ala Arg Tyr Cys Phe Val Glu Asn Met Arg Arg Asn Gly Ser Leu Glu	
100 105 110	
cag ggc atg tac aat acg ctg gag gag tgg tac aag ttc atc gaa gag	384
Gln Gly Met Tyr Asn Thr Leu Glu Trp Tyr Lys Phe Ile Glu Glu	
115 120 125	
tcc att cac gtg cag gcg gac ctc atc ata tat ctg cgc acc tcg ccg	432
Ser Ile His Val Gln Ala Asp Leu Ile Ile Tyr Leu Arg Thr Ser Pro	
130 135 140	
gag gtg gcg tac gaa cgc atc cgg cag cgg gct cgt tct gag gag agc	480
Glu Val Ala Tyr Glu Arg Ile Arg Gln Arg Ala Arg Ser Glu Glu Ser	
145 150 155 160	
tgc gtg ccg ctt aag tac ctt cag gag ctg cat gag ttg cac gag gac	528
Cys Val Pro Leu Lys Tyr Leu Gln Glu Leu His Glu Leu His Glu Asp	
165 170 175	
tgg ttg ata cac cag aga cga ccg cag tcg tgc aag gtc cta gtc ctc	576
Trp Leu Ile His Gln Arg Arg Pro Gln Ser Cys Lys Val Leu Val Leu	
180 185 190	
gat gcc gat ctg aac ctg gaa aac att ggc acc gag tac cag cgc tcg	624
Asp Ala Asp Leu Asn Leu Glu Asn Ile Gly Thr Glu Tyr Gln Arg Ser	
195 200 205	
gag agc agc ata ttc gac gcc atc tca agt aac caa cag ccc tcg ccg	672
Glu Ser Ser Ile Phe Asp Ala Ile Ser Ser Asn Gln Gln Pro Ser Pro	
210 215 220	
gtt ctg gtg tcg ccc agc aag cgc cag agg gtc gcc aga	711
Val Leu Val Ser Pro Ser Lys Arg Gln Arg Val Ala Arg	
225 230 235	

<210> 10  
 <211> 237  
 <212> PRT  
 <213> hybrid

<400> 10  
 Met Ser Ala Asn Asn Val Lys Pro Phe Thr Val Phe Val Glu Gly Asn  
           1                  5                  10                  15  
 Ile Gly Ser Gly Lys Thr Thr Phe Leu Glu His Phe Arg Gln Phe Glu  
                   20                  25                  30  
 Asp Ile Thr Leu Leu Thr Glu Pro Val Glu Met Trp Arg Asp Leu Lys  
                   35                  40                  45  
 Gly Cys Asn Leu Leu Glu Leu Met Tyr Lys Asp Pro Glu Lys Trp Ala  
           50                  55                  60  
 Met Thr Phe Gln Ser Tyr Val Ser Leu Thr Met Leu Asp Met His Arg  
           65                  70                  75                  80  
 Arg Pro Ala Pro Thr Pro Val Lys Leu Met Glu Arg Ser Ile Phe Ser  
                   85                  90                  95  
 Ala Arg Tyr Cys Phe Val Glu Asn Met Arg Arg Asn Gly Ser Leu Glu  
                   100                  105                  110  
 Gln Gly Met Tyr Asn Thr Leu Glu Glu Trp Tyr Lys Phe Ile Glu Glu  
           115                  120                  125  
 Ser Ile His Val Gln Ala Asp Leu Ile Ile Tyr Leu Arg Thr Ser Pro  
           130                  135                  140  
 Glu Val Ala Tyr Glu Arg Ile Arg Gln Arg Ala Arg Ser Glu Glu Ser  
           145                  150                  155                  160  
 Cys Val Pro Leu Lys Tyr Leu Gln Glu Leu His Glu Leu His Glu Asp  
                   165                  170                  175  
 Trp Leu Ile His Gln Arg Arg Pro Gln Ser Cys Lys Val Leu Val Leu  
                   180                  185                  190  
 Asp Ala Asp Leu Asn Leu Glu Asn Ile Gly Thr Glu Tyr Gln Arg Ser  
           195                  200                  205  
 Glu Ser Ser Ile Phe Asp Ala Ile Ser Ser Asn Gln Gln Pro Ser Pro  
           210                  215                  220  
 Val Leu Val Ser Pro Ser Lys Arg Gln Arg Val Ala Arg  
           225                  230                  235

<210> 11  
 <211> 786  
 <212> DNA  
 <213> hybrid

<220>  
 <221> CDS  
 <222> (1)..(786)  
 <223> 1-309 Drosophila melanogaster; 310-786 Bombyx  
           mori.

## 10

&lt;400&gt; 11

atg gcg gag gca gca tcc tgt gcc cga aag ggg acc aag tac gcc gag	48
Met Ala Glu Ala Ala Ser Cys Ala Arg Lys Gly Thr Lys Tyr Ala Glu	
1 5 10 15	
ggc acc cag ccc ttc acc gtc ctc atc gag ggc aac atc ggc agc ggg	96
Gly Thr Gln Pro Phe Thr Val Leu Ile Glu Gly Asn Ile Gly Ser Gly	
20 25 30	
aag acc acg tat ttg aac cac ttc gag aag tac aag aac gac att tgc	144
Lys Thr Thr Tyr Leu Asn His Phe Glu Lys Tyr Lys Asn Asp Ile Cys	
35 40 45	
ctg ctg acc gag ccc gtc gag aag tgg cgc aac gtc aac ggg gta aat	192
Leu Leu Thr Glu Pro Val Glu Lys Trp Arg Asn Val Asn Gly Val Asn	
50 55 60	
ctg ctg gag ctg atg tac aaa gat ccc aag aag tgg gcc atg ccc ttt	240
Leu Leu Glu Leu Met Tyr Lys Asp Pro Lys Lys Trp Ala Met Pro Phe	
65 70 75 80	
cag agt tat gtc acg ctg acc atg ctg cag tcg cac acc gcc cca acc	288
Gln Ser Tyr Val Thr Leu Thr Met Leu Gln Ser His Thr Ala Pro Thr	
85 90 95	
aac aag aag cta aaa ata atg gag cga tca tta ttc agt gcg aga tac	336
Asn Lys Lys Leu Lys Ile Met Glu Arg Ser Leu Phe Ser Ala Arg Tyr	
100 105 110	
tgc ttc gtt gaa cac att atg aga aat aat aca ctc cat cca gca cag	384
Cys Phe Val Glu His Ile Met Arg Asn Asn Thr Leu His Pro Ala Gln	
115 120 125	
ttt gca gta ctt gat gag tgg ttc cga ttc atc caa cac aac att cct	432
Phe Ala Val Leu Asp Glu Trp Phe Arg Phe Ile Gln His Asn Ile Pro	
130 135 140	
att gat gct gat ttg ata gta tat cta aag aca tca cct tca ata gtg	480
Ile Asp Ala Asp Leu Ile Val Tyr Leu Lys Thr Ser Pro Ser Ile Val	
145 150 155 160	
tac caa agg ata aaa aag aga gct cgt tca gaa gag cag tgt gtg ccc	528
Tyr Gln Arg Ile Lys Lys Arg Ala Arg Ser Glu Glu Gln Cys Val Pro	
165 170 175	
ctg tca tac att gag gaa ctg cat agg ttg cat gag gac tgg cta atc	576
Leu Ser Tyr Ile Glu Glu Leu His Arg Leu His Glu Asp Trp Leu Ile	
180 185 190	
aac agg ata cat gct gaa tgt ccc gca cca gta tta gtg tta gat gct	624
Asn Arg Ile His Ala Glu Cys Pro Ala Pro Val Leu Val Leu Asp Ala	
195 200 205	
gat tta gac ctc tct cag ata acc gat gaa tac aag aga agt gag cat	672
Asp Leu Asp Leu Ser Gln Ile Thr Asp Glu Tyr Lys Arg Ser Glu His	
210 215 220	
caa att tta aga aag gct gtt aat gta gtt atg agt tca cca aac aag	720
Gln Ile Leu Arg Lys Ala Val Asn Val Val Met Ser Ser Pro Asn Lys	
225 230 235 240	
cat agc cca aag aaa cca ata tca aca aca cca atc aag atc aca cct	768
His Ser Pro Lys Lys Pro Ile Ser Thr Thr Pro Ile Lys Ile Thr Pro	
245 250 255	

cac atg agg atc tta taa  
His Met Arg Ile Leu  
260

786

<210> 12  
<211> 261  
<212> PRT  
<213> hybrid

<400> 12  
Met Ala Glu Ala Ala Ser Cys Ala Arg Lys Gly Thr Lys Tyr Ala Glu  
1 5 10 15  
Gly Thr Gln Pro Phe Thr Val Leu Ile Glu Gly Asn Ile Gly Ser Gly  
20 25 30  
Lys Thr Thr Tyr Leu Asn His Phe Glu Lys Tyr Lys Asn Asp Ile Cys  
35 40 45  
Leu Leu Thr Glu Pro Val Glu Lys Trp Arg Asn Val Asn Gly Val Asn  
50 55 60  
Leu Leu Glu Leu Met Tyr Lys Asp Pro Lys Lys Trp Ala Met Pro Phe  
65 70 75 80  
Gln Ser Tyr Val Thr Leu Thr Met Leu Gln Ser His Thr Ala Pro Thr  
85 90 95  
Asn Lys Lys Leu Lys Ile Met Glu Arg Ser Leu Phe Ser Ala Arg Tyr  
100 105 110  
Cys Phe Val Glu His Ile Met Arg Asn Asn Thr Leu His Pro Ala Gln  
115 120 125  
Phe Ala Val Leu Asp Glu Trp Phe Arg Phe Ile Gln His Asn Ile Pro  
130 135 140  
Ile Asp Ala Asp Leu Ile Val Tyr Leu Lys Thr Ser Pro Ser Ile Val  
145 150 155 160  
Tyr Gln Arg Ile Lys Lys Arg Ala Arg Ser Glu Glu Gln Cys Val Pro  
165 170 175  
Leu Ser Tyr Ile Glu Glu Leu His Arg Leu His Glu Asp Trp Leu Ile  
180 185 190  
Asn Arg Ile His Ala Glu Cys Pro Ala Pro Val Leu Val Leu Asp Ala  
195 200 205  
Asp Leu Asp Leu Ser Gln Ile Thr Asp Glu Tyr Lys Arg Ser Glu His  
210 215 220  
Gln Ile Leu Arg Lys Ala Val Asn Val Val Met Ser Ser Pro Asn Lys  
225 230 235 240  
His Ser Pro Lys Lys Pro Ile Ser Thr Thr Pro Ile Lys Ile Thr Pro  
245 250 255  
His Met Arg Ile Leu  
260

## 12

<210> 13  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence  
  
<400> 13  
acgtttggtg gtggcgacca 20  
  
<210> 14  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence  
  
<400> 14  
ctccgggagc tgcattgtgc 20  
  
<210> 15  
<211> 38  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence  
  
<400> 15  
ctaaaaatgg agcgctccat tagctttact ggagttgg 38  
  
<210> 16  
<211> 35  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence  
  
<400> 16  
ccagtaaagc taatggagcg ctccattttt agcgc 35  
  
<210> 17  
<211> 35  
<212> DNA  
<213> Artificial Sequence  
  
<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence  
  
<400> 17  
gaataatgat cgctccatta tttttagctt cttgt 35

<210> 18  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence

<400> 18  
aagctaaaaa taatggagcg atcattattc agtgc 35

<210> 19  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence

<400> 19  
tatcgcgat ccatgagtc caacaatgtt aaaccattca cc 42

<210> 20  
<211> 46  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR primer  
sequence

<400> 20  
ccggaattcg tcgacttata agatcctcat gtgaggtgtg atcttg 46



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**